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5. ABSTRACT
Systemic amyloidosis is an infiltrative disorder caused by amyloid deposition in the
extracellular space. Two main types of systemic amyloidosis affect the ventricular
myocardium, immunoglobulin light chain (AL) and transthyretin (ATTR). These have
different natural histories and prognosis but in both, cardiac involvement is the main driver
of outcome. For cardiac amyloidosis, Cardiovascular Magnetic Resonance (CMR) with the
late gadolinium enhancement (LGE) technique provides sensitivity for early detection but
is highly dependent on operator skills and not quantitative - there is no current method of
measuring cardiac amyloid burden. A new technique, T1 mapping permits tissue
abnormalities to be directly visualised in a simple scan – the colour changes being
instantly recognisable, either before contrast (native T1 mapping) or after, when the
myocardial extracellular volume (ECV) can be measured. Furthermore, a widely available
LGE approach, phase sensitive inversion recovery (PSIR) LGE, being less operator
dependent, had potential for improved performance.
At the National Amyloidosis Centre and Heart Hospital collaboration, I explored:
1- The potential of a new, faster T1 mapping sequence (ShMOLLI).
2- The potential of native T1 mapping for diagnosing cardiac ATTR and AL
amyloidosis.
3- The inferred pathophysiology of cardiac amyloidosis by characterising amyloid
burden, oedema and myocyte response concurrently.
4- The use of the LGE PSIR approach to improve the LGE technique.
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In technical development, I showed that ShMOLLI T1 mapping can more accurately
and precisely measure the ECV in various heart diseases including amyloid. Compared to
the older multibreath-hold technique, more patients were able to perform ShMOLLI (6%
unable to do multibreath-hold); the two techniques correlated (r2=0.89) with little bias (-
2.2%) and good agreement (ICC 0.92, p<0.0001) but ShMOLLI ECV correlated better with
histological collagen volume fraction (CVF) ( r2= 0.68 vs r2= 0.59) with a trend to better
inter-study reproducibility (95%CI -4.9% to 5.4% vs -6.4% to 7.3% respectively, p=0.21).
I then explored native T1 mapping to detect cardiac infiltration in amyloidosis. For
ATTR amyloidosis, T1 was elevated compared to hypertrophic cardiomyopathy (HCM) or
normal subjects (1097±43ms vs 1026±64ms vs 967±34ms, both p<0.0001). This elevation
was not as high as in AL amyloidosis (AL 1130±68ms, p=0.01). Diagnostic performance
was similar for AL and ATTR amyloidosis (vs HCM: AL AUC 0.84 (95%CI 0.76-0.92);
ATTR 0.85 (0.77-0.92) P<0.0001). T1 tracked cardiac amyloid burden as determined
semi-quantitatively by DPD scintigraphy (p<0.0001). T1 was not elevated in mutation
carriers (952±35ms) but was in isolated DPD grade 1 (n=9, 1037±60ms, p=0.001).
I then used T1 mapping with contrast (and without) to measure the ECV and
combined this information with myocardial mass and native T1. I could, for the first time,
non-invasively measure the amyloid burden (ECV) and myocyte volume ((ECV-
1)*LVmass). Both LV massi and ECV were markedly elevated in amyloidosis. However,
the Total Cell Volume was normal in AL, 47±17 ml/m2, but elevated in ATTR, 53±12 ml/m2
(p<0.05). This implies that all the (lesser) LV mass increase in AL is ECV i.e. amyloid,
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whereas the (greater) increase in ATTR is mainly extracellular but with an additional 18%
intra-cellular increase – likely myocytes, the dominant (by volume) myocardial cell type.
I then revisited the LGE technique in amyloid. This has always been difficult as
nulling often seems to fail in amyloid. Using PSIR, a new, potentially more robust LGE
approach, I assessed the incremental prognostic value of LGE. 250 prospectively recruited
subjects underwent LGE CMR comprising 122 with ATTR amyloid, 9 asymptomatic
mutation carriers, and 119 patients with AL amyloidosis. Subjects were followed up for a
mean of 24 months. LGE was performed with PSIR and without (magnitude only, MAG-
IR). These were compared with ECV with ShMOLLI. PSIR was superior to MAG-IR LGE
since PSIR nulled always the tissue (blood or myocardium) with the longest T1 (least
gadolinium). LGE was classified into 3 patterns: none, subendocardial and transmural,
which were associated with increasing amyloid burden as defined by ECV (p<0.0001) with
transitions from none to subendocardial LGE at an ECV of 0.40-0.43(AL), 0.39-
0.40(ATTR); and to transmural at 0.48-0.55(AL), 0.47-0.59(ATTR). Sixty seven (27%)
patients died. Transmural LGE predicted death (HR=5.4, 95%CI: 2.1-13.7,p<0.0001) and
remained independent after adjusting for NT-proBNP, ejection fraction, stroke volume
index, E/E’ and LV mass index (HR=4.1, 95%CI: 1.3-13.1,p<0.05).
In conclusion, the work in this thesis has enabled a deeper understanding of
cardiac amyloidosis, disease processes and stages. Cardiac amyloidosis is not just
infiltration, but there appears to be a myocyte response. It has pioneered the clinical use
of native T1, ECV and LGE PSIR, new markers that are able to identify and quantify
cardiac involvement and give new insights in the pathophysiology of cardiac disease.
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6. INTRODUCTION
This chapter is based on the publication below:
Fontana M, Chung R, Hawkins PN, Moon JC. Cardiovascular magnetic resonance for amyloidosis.
Heart Fail Rev. 2015 Mar;20(2):133-44.
My contribution was writing the review.
6.1WHAT IS AMYLOID
Amyloidosis is a group of diseases characterised by the deposition of amyloid in one or
more organs. As many as 23 different precursor proteins to the formation of amyloid have
been described in man.(1) These may deposit themselves in a fibrillar matrix within
selected tissues. Fibril formation is also associated with deposition of other nonfibrillar
substances, notably including glycosaminoglycans and serum amyloid P-component
amongst others.(2) Fibrils are formed when normally soluble molecules undergo
conformational change and mis-fold to become relatively insoluble, resulting in the
deposition of nonbranching fibrils in different organs.(3) Amyloid deposition into the heart
is the leading cause of death and influences therapeutic choices.(4)
Amyloid deposits can be massive and cardiac or other tissues may become
substantially replaced. Amyloid fibrils bind Congo red stain, yielding the pathognomonic
apple-green birefringence under cross-polarized light microscopy that remains the gold
standard for identifying amyloid deposits. Further staining with immunohistochemistry is
performed to subtype into the 2 main types which affect ventricular myocardium, AL and
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ATTR amyloidosis, the latter comprising two forms, wild type or genetically variant – both
forms of transthyretin.
6.2PRIMARY AL AMYLOIDOSIS
Primary AL amyloidosis occurs most often in the setting of a plasma cell dyscrasia, in
which circulating amyloidogenic light chains deposit within extracellular space of different
organs causing damage.
Cardiac AL amyloidosis may be rapidly progressive. Low QRS voltages, particularly
in the limb leads are common. Thickening of the left ventricular wall is typically mild to
moderate, and is rarely greater than 18mm, even in advanced disease. Cardiac AL
amyloid deposition is accompanied by marked elevation of the brain natriuretic peptide
(BNP/NT-proBNP) and cardiac troponins, even at an early stage. The right heart failure is
often exacerbated by the co-presence of nephrotic syndrome in 30-50% of cases.(5) The
hypoalbuminaemia of nephrotic syndrome is itself exacerbated by concomitant liver
disease. Hypotension can be present not only because of a “low-output” state, but also
because of associated autonomic neuropathy.
Involvement of the heart is the commonest cause of death in AL amyloidosis, and a
major determinant of prognosis: without cardiac involvement, AL amyloidosis has a
median survival of around 4 years (6) but with, (e.g. elevated BNP and cardiac Troponin -
Mayo stage III disease) (7) It is 6-8 months.
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Like all cardiac amyloid, treatment to arrest amyloid deposition may halt disease
progression and improve blood biomarkers, but echocardiography, CMR and ECG
changes rarely revert.
6.3HEREDITARY TRANSTHYRETIN-RELATED AMYLOIDOSIS
TTR is a small tetramer synthesised in the liver that transports thyroxine and
retinol.(8) Myocardial infiltration can be severe, causing overt heart failure. A
sensorimotor/autonomic neuropathy frequently co-exists(9).Over 100 mutations are
recognised and each mutation can display variable penetrance.(9) For example, the
substitution of isoleucine for valine at the position 122 (V122I) occurs in up to 4% of Afro-
Caribbeans in London causing eventual cardiac amyloidosis in an unknown
proportion.(10) Echocardiography shows restrictive left ventricular features usually with
preserved systolic function.(10) This is often mistaken for hypertensive heart disease. In
around half of African-Caribbean patients with heart failure the ejection fraction is normal
(11) and early evidence suggests that this may be due to undiagnosed cardiac amyloid.
Imaging features of ATTR are not known to specify the amyloid subtype (although see
DPD scanning, and my CMR results, later), but patients with ATTR typically have fewer
symptoms and better survival than AL amyloid patients. (11)
6.4WILD TYPE TRANSTHYRETIN AMYLOIDOSIS
Non-hereditary TTR-related amyloidosis is commonly referred to as Senile
Systemic Amyloidosis (SSA) owing to its late age of onset (after the seventh decade of
life) or wild type transthyretin amyloidosis. Wild-type TTR amyloid deposits are found at
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autopsy in about 25% of individuals older than 80 years, but their clinical significance is
not clear.(12-14) Epidemiological studies assessing the prevalence of wild type TTR
deposits leading to the clinical syndrome of SSA have not been performed. SSA is a
predominant cardiac disease often preceding heart failure by 3-5 years.(15) There is a
strong male predominance, and like hereditary ATTR, it is often misdiagnosed as
hypertensive heart disease.(16) The natural history remains poorly understood, but studies
suggest a median survival of about 7 years from presentation. (12,13)The true incidence of
SSA is probably underestimated, a gap that is being filled by recent advances in CMR to
improve detection of cardiac amyloid – for example, until 2001, it accounted for 0.5% of all
patients seen at the UK amyloidosis centre, but now accounts of 7% of 1100 cases with
amyloidosis seen since end of 2009 (unpublished data).
6.5DIAGNOSIS AND EVALUATION OF CARDIAC AMYLOIDOSIS
6.5.1 ELECTROCARDIOGRAPHY (ECG):
Low QRS voltages (all limb leads <5 mm in height) with poor R wave progression in
the chest leads (pseudoinfarction pattern) occur in up to 50% of patients with cardiac AL
amyloidosis.(17) The combination of low ECG voltage with increased wall thickness is
highly suspicious for cardiac amyloidosis (see figure 1), but voltage criteria for left
ventricular hypertrophy (LVH) can occur.(18,19). The mechanisms are poorly understood,
but a possible hypothesis links low voltages with the myocyte loss associated with amyloid
infiltration (see my results).
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Figure 1. ECG of a patient with cardiac AL Amyloidosis.
Small QRS voltages (defined as <5mm height) in the limb leads.
Other findings include various degrees of AV blocks and intraventricuar blocks
(more frequent in ATTR than AL): first degree atrioventricular (AV) block (21%),
nonspecific intraventricular conduction delay (16%), second or third degree AV block (3%);
(18) left (LBBB) and right bundle branch block can also occur.(20) Rhythm disturbances
are frequent as well including AF/flutter (20%) and ventricular tachycardia (VT) (5%).ECG
patterns can provide clues to differentiate between AL and ATTR amyloidosis: LBBB is
seen in 40% of patients with wild type ATTR but is rare in AL (4%), while typical low QRS
voltages are seen in 40% wild type ATTR vs 60% AL.(4)
There has been little recent study of ECG correlation with cardiac biomarkers,
treatment toxicity and mortality. Progressive ECG changes may be useful in assessing
silent cardiac progression.(21) Changes in ECG abnormalities after treatment in AL
amyloidosis remain poorly studied, but can occur – more often, little improvement is seen.
Holter ECG monitoring identifies asymptomatic arrhythmias in >75% of cardiac AL patients
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(mainly supraventricular tachyarrhythmias and some non-sustained VT), but the prognostic
significance is unknown.(22)
6.5.2 ECHOCARDIOGRAPHY
Echocardiography is the first line imaging modality where the suspicion of cardiac
amyloidosis is raised. Findings are only characteristic in advanced disease when the
study is performed by experienced operators, but harder to detect earlier on and have
prognostic and diagnostic significance.(23-25) Typical findings include concentric LVH with
right ventricular (RV) involvement, poor biventricular long axis function with mildly reduced
ejection fraction (EF) (26,27), valvular and interatrial septal thickening.(4) Diastolic
dysfunction is the earliest echocardiographic abnormality, may occur before cardiac
symptoms develop but the specificity of these findings is poor (28,29).
Advanced echocardiographic techniques are beginning to reveal more about the
underlying pathology and functional abnormalities, such as the twisting and untwisting
cardiac motion that may be augmented through compensatory mechanisms before
reversing to impairment later in the course of the disease.(30,31) Strain and strain rate
imaging, derived from speckle tracking (see figure 2), may improve the specificity of
echocardiographic findings, helping differentiate cardiac amyloidosis from hypertrophic
cardiomyopathy.(32,33). Typically, there is much greater restriction of basal than apical
movement. Mean LV basal strain is an independent predictor of both cardiac and overall
deaths.(34)
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Figure 2. Transthoracic echocardiogram with speckle tracking.
The red and yellow lines represent longitudinal motion in the basal segments while the purple and
green lines are apical motion. This shows loss of longitudinal ventricular contraction at the base
compared to apex.
6.5.3 CARDIAC BIOMARKERS
Measurements of brain natriuretic peptides (BNP/NT-proBNP) and cardiac
troponins are informative in AL amyloidosis, where most study has occurred to date. Their
value in ATTR amyloidosis is yet to be determined. Brain natriuretic peptides are cleared
by the kidneys (BNP also partially cleared by the liver), confounding the evaluation of
patients with kidney involvement. Elevated NT-proBNP levels in systemic AL amyloidosis
are a sensitive marker of cardiac involvement, with a cut-off >152pmol/L being associated
26
with higher mortality (72% vs 7.6% per year).(35) Abnormal NT-proBNP is predictive of
clinically significant cardiac involvement developing in future.(36)
Increased troponin is a marker of poor prognosis (37) but the mechanism remains
unclear.(37) Indeed more recently, high-sensitivity Troponin T has been shown to correlate
with morbidity and mortality after patients with renal impairment were excluded.(38) High-
sensitivity Troponin is abnormal in more than 90% of cardiac AL patients (39) and the
combination of brain natriuretic peptides plus troponin measurements are used to stage
and risk-stratify patients with AL amyloidosis at diagnosis.(7,40)
Interestingly, the concentration of brain natriuretic peptides in AL amyloidosis may
fall dramatically within weeks following chemotherapy that substantially reduces the
production of amyloidogenic light chains.(41) The basis for this very rapid phenomenon,
which is not mirrored by changes on echocardiography or CMR remains uncertain, but a
substantial fall is associated with improved outcomes.(42) An early transient increase in
brain natriuretic peptides may occur after treatment with the immunomodulatory drugs
thalidomide and lenalidomide, which are frequently used in the management of AL
amyloidosis (see later), but the significance and cause is unclear.(43,44)
6.5.4 RADIONUCLIDE IMAGING
Serum amyloid P component (SAP) scintigraphy uses purified human SAP
radiolabelled with 123I, which is injected into patients. The tracer localises to target organs
rich in amyloid and an image captured with a gamma camera. SAP scans enable visceral
amyloid deposits, including those in the liver, kidneys, spleen, adrenal glands and bones
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to be imaged serially in a specific and qualitative manner.(45) It does not adequately
image the heart and thus has no role in assessing cardiac amyloidosis.
Numerous case reports over the past 30 years have indicated that various
commonly used diphosphonate bone seeking radionuclide tracers occasionally localise to
cardiac amyloid, and this approach has now been investigated systematically and now
used routinely in clinical practice. Technetium-labelled 3,3-diphosphono-1,2-
propanodicarboxylic acid bone scanning agent (99mTc-DPD), a particular tracer that has
been little used of late for bone scintigraphy, appears to localise to cardiac amyloid
deposits very sensitively, especially in patients with ATTR type (figure 3), where it has
become the gold standard imaging test for cardiac ATTR amyloid. Indeed, asymptomatic
cardiac ATTR deposits can be identified through 99mTc-DPD scintigraphy at an early stage
when echocardiography, serum cardiac biomarkers and perhaps even CMR remain
normal. 82
Uptake of 99mTc-DPD occurs in fewer (about one third) of patients with cardiac AL
amyloidosis at lower grade. 99mTc-DPD-SPECT-CT can help to distinguish the two
types.(46) The sensitivity of DPD scintigraphy for detecting cardiac amyloidosis of ATTR
type would appear to have considerable potential for diagnosis and screening.(47) Early
work using N-[methyl-(11)C]2-(4’-methylamino-phenyl)-6-hydroxybenzothiazole ((11)C-
PIB) PET imaging for cardiac amyloidosis is promising.(48) Currently, because of the
much lower sensitivity of DPD scintigraphy in AL compared with ATTR amyloidosis, a
multimodality imaging approach is adopted using radionuclide scintigraphy, along with
echocardiography and cardiac MRI as described below.
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Figure 3. 99mTc-DPD scan in ATTR cardiac amyloidosis.
A positive 99mTc-DPD scan for ATTR cardiac amyloidosis (left), showing uptake in the heart (arrow)
and reduced bone uptake. The right hand panel showed a fused CT/SPECT image showing
myocardial uptake with greater uptake in the septum.
6.5.5 CARDIAC MRI
CMR uses a superconducting magnet with ECG gating to investigate the heart, gaining
insight into the extra cardiac anatomy, cardiac structure, function and specific
characterisations of myocardial tissue. As a test, it may have high sensitivity and
specificity, but the diagnostic yield and importance of findings depends on the pre-test
probability. Advanced cardiac amyloidosis is easy to detect by any technique: the
detection of earlier cardiac involvement and their differentials from other phenocopies or
genocopies may be harder. CMR, like other tests should therefore be interpreted in the
clinical context. Specific differentials or disease processes that may raise diagnostic
problems and confounders are co-morbidities (age, renal failure, diabetes, hypertension);
whether there is another cardiomyopathy such as HCM or dual pathology, eg aortic
stenosis and wild type ATTR amyloidosis.
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Extracardiac anatomy: Cardiac amyloidosis is frequently associated with other
abnormalities. Pleural effusions are common, as is ascites in advanced disease (Figure
4). Effusions and ascites when there is apparently good cardiac function (normal ejection
fraction) are signs of heart failure with preserved ejection fraction (HFpEF) - one cause of
which is amyloidosis. However, by the time patients are referred for CMR, many have
frequently started heart failure treatment and may occasionally have ascites without
pleural effusions (figure 4). Nephrotic syndrome, from renal involvement in AL amyloidosis,
is yet another manifestation. Patchy lung changes are not infrequently seen, but many
patients are elderly, and CMR is not adequate to diagnose lung infiltration (figure 4).
Occasionally the presence of increased gas in the bowel or dilated oesophagus from
autonomic dysfunction can be seen. Similarly, liver changes are occasionally seen – fatty
liver with its featureless hypovascular appearance is an occasional finding in patients with
known AL amyloidosis (figure 4).
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Figure 4. Extracardiac findings in patients with cardiac amyloidosis.
Panel a: pleural and pericardial effusions. Panel b: ascites without pleural effusions. Panel c: Right
pleural effusion. Panel d: lardaceous fatty liver with its featureless hypovascular appearance.
Panel e: tortuous and dilated thoracic aorta, frequently seen in hypertension, one of the main
differentials. Panel f: patchy lung changes (non-specific by CMR).
Morphology, function and anatomy: Traditionally cardiac amyloidosis has been thought to
be characterized by concentric and symmetric hypertrophy of the left ventricle as opposed
to apical or asymmetric wall thickening in HCM (figure 5). However, recent work
documents concentric LVH in 59% of patients with cardiac amyloidosis, as well as
eccentric LVH or concentric remodelling in 33% and normal geometry in the remaining 8%
(49). Cardiac amyloidosis may present with both symmetric and asymmetric, concentric
and eccentric hypertrophy (Figure 5). Hypertrophy may be disproportionately greater than
in hypertension (e.g. greater than ~17 mm) and is more prominent in ATTR than AL
amyloid. RV involvement with hypertrophy is frequent - the RV end systolic thickness may
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be up to 1 cm. A few cases have been observed with a dilated cardiomyopathy phenotype
(again with classical tissue characterisation findings) (figure 5), and occasionally patients
have outflow tract obstruction. Thus, although many cases are characteristic, the full
range of morphological findings in amyloid is broad.
Figure 5. Left ventricular remodelling phenotypes in cardiac amyloidosis.
For each pattern there is an example of a cine four chamber view and a short axis late gadolinium
enhancement. Left upper panel: symmetric hypertrophy, traditionally considered the characteristic
pattern. Right upper panel: asymmetric hypertrophy, recently proven to be highly prevalent in
cardiac amyloidosis. Left lower panel: dilated cardiomyopathy phenotype (rare-described in few
cases). Right lower panel: no left ventricular hypertrophy with late gad features of amyloidosis, a
less uncommon finding that is hard to detect without tissue characterisation.
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Traditional markers such as ejection fraction may be normal even into the late phase of
disease because it is a poor measure of systolic function in patients with concentric
remodelling. Long axis function (typically biventricular) reduces early, mainly at the level
of the basal segments. The reduction, in many cases to effectively zero longitudinal
function, is associated with small cavity size, decreased stroke volume and reduced
cardiac output (50). The indexed stroke volume, usually severely reduced, is therefore a
better measure of systolic function than the ejection fraction, and we would recommend
scrutinising it in reports of possible cardiac amyloid.
CMR is less adept than echocardiography for diastolic function assessment.
Valvular disease in cardiac amyloidosis seems no more prevalent than in other people of
similar age. Atrial infiltration definitely occurs, but CMR shows that much of the apparent
atrial thickening in amyloidosis is interatrial fat. In later phases, atrial fibrillation, particularly
coarse or flutter-like fibrillation may be observed and thrombi may be seen in the left atrial
appendage. The severe reduction in the atrial contraction characteristic of later stages is
often associated with signs of very slow flow (“smoke”) in the left atrium and also occurs in
patients in sinus rhythm.
Serial imaging studies provide additional insight into the time course of amyloidosis.
Swiftly changing cardiac hypertrophy is not common in cardiomyopathy in adult life
(although late onset HCM is well known), but rapid changes over months in wall thickness
and function, should place AL amyloidosis high on the differential list. Although CMR-
based morphological and functional assessment is probably more accurate than with
echocardiography alone (with the important exception of diastolic dysfunction and strain
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measurement) (34), these features are nonspecific and vary in prevalence until late
phases of disease. Thus, in high pre-test probability scenarios, the absence of these
morphological and functional markers does not fully exclude cardiac amyloidosis (49).
Tissue characterisation: A key advantage of CMR is its unique ability to give information
about the tissue composition by “myocardial tissue characterization”. Healthy and
pathological myocardium may differ because of “intrinsic contrast” (without the use of
gadolinium) - signal difference from the myocardium as pathology changes the myocardial
T1, T2 and T2*. Alternatively, the addition of an extrinsic gadolinium-based contrast agent
Gd-DTPA (gadolinium diethylenetriamine penta-acetic acid) may reveal “extrinsic contrast”
properties as in the LGE. The gadolinium component alters the CMR signal and the
chelator makes it inert and determines the in vivo properties of the whole, determining the
tracer behaviour (51). These purely extracellular agents are small enough to pass across
the vascular wall into the extracellular space, yet are large enough to not penetrate
myocardial cells with intact membranes. It accumulates passively in the gaps between
cells through post-bolus tracer kinetics and the increased volume of distribution (interstitial
expansion) in hydrated ‘scar’ tissue or in areas of amyloid deposition (52). After
gadolinium, in normal tissue, the whole myocardium will have a diffuse lowering of T1. In
scar/focal amyloid there will be areas where the T1 is regionally detectably lower, the basis
of the LGE technique for qualitative detection of focal fibrosis (e.g. myocardial infarction).
In diffuse infiltration, the whole myocardium will have substantially lower T1 – which was a
problem until the development of the extracellular volume (ECV) technique.
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The typical” amyloid LGE pattern” is global subendocardial LGE in a non-coronary
artery territory distribution with a dark blood pool, but this can vary. (53) Patterns vary in
different series:(52,54-57) some find mainly localised enhancement; others diffuse
transmural or patchy LGE (53,58,59) (figure 5 and 6). Thus, despite there being a ”typical
LGE pattern” in amyloid, current research suggests a more variable LGE pattern. Recent
studies separating ATTR from AL are more informative. LGE (when classical) can be
virtually pathognomonic and significantly more specific and sensitive than echo or CMR
functional assessment. This can even be an apparently early finding – some patients are
seen where the classical LGE appearance is present without hypertrophy (figure 5).
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Figure 6. Late gadolinium enhancement.
LGE with magnitude (MAG) reconstruction (left panels) and LGE with phase sensitive inversion
recovery reconstruction (PSIR) (right panels). There is discordance between magnitude and PSIR
reconstruction in the three examples. ECV mapping (not shown) can arbitrate – the areas of the
highest ECV are the ones that should show LGE and PSIR always gets this right. Upper panels:
the MAG looks normal; the PSIR shows transmural LGE, concordant with an ECV here of >0.5, not
shown. Middle panels: the MAG (patchy more apical LGE) is a mirror of the PSIR (more apical).
Lower panels: the MAG (subepicardial LGE, circle) is a mirror image of the true PSIR pattern.
The traditional LGE technique is a difference test for focal lowering of T1Infiltrative
diseases, especially amyloid, that affect the entire myocardium may have no remote
regions of normal myocardium. This exposes a pitfall of the traditional approach in that the
operator determining the optimal null-point for the myocardium may erroneously choose to
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null the abnormal and not the normal myocardium. This can result in a serious risk of false
negative examinations (when the entire myocardium is involved but could appear as
normal) or “wrong” LGE patterns (i.e. mirror image of the true pattern, with mid-myocardial
patterns becoming subendocardial and vice versa), potentially contributing to the variable
LGE patterns described (figure 6).
The relatively new approach of Phase Sensitive Inversion Recovery (PSIR)
sequence (60), now available from almost all the CMR manufacturers, could reduce the
need for a optimal null point setting, making LGE in cardiac amyloidosis far easier and
operator-independent (Figure 4). This approach is likely to improve the diagnostic and
prognostic performance on “true” LGE patterns of cardiac amyloidosis, with the potential to
reduce heterogeneity in the patterns reported (Figure6). I explore this later (chapter 11)
However the use of gadolinium is relatively contraindicated in patients with severe
renal failure (estimated glomerular filtration rate, eGFR, <30 ml/min - a relatively common
finding in patients with systemic AL amyloidosis). LGE in non-ischaemic cardiomyopathy,
especially amyloid, is not easy to quantify so it is not reliable for following up changes over
time. Newer T1 mapping techniques may overcome these limitations.
T1 mapping is a new technique where direct quantitative signal from the
myocardium is measured, either pre-contrast (native T1) or post-contrast. Each pixel in
the image is coded in colour, reflecting the absolute value of T1 (Figure 7). Native
myocardial T1 mapping therefore measures myocardial intrinsic signal and T1 “maps” in a
single breath-hold (61). Pathology changes native T1. Reduced T1 is uncommon,
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occurring only in iron overload (62) and fat infiltration such as Fabry disease (FD] (63)
(64). Increases in native T1 occurs: modestly in diffuse fibrosis, more in scar and
substantially in amyloid and oedema – with good signal to noise ratio (figure 7). Native
myocardial T1 mapping is associated in single centre studies with a high diagnostic
accuracy for cardiac amyloidosis for AL when compared against patients with LVH from
different causes such as aortic stenosis (63,65) (Figure 7). This may find clinical utility
particularly when gadolinium contrast is contraindicated. In AL amyloidosis, T1 tracks
markers of systolic and diastolic function, mass and prognostic markers (66). T1 is an
early disease marker, being elevated before the onset of LVH, presence of LGE or
elevation in blood biomarkers. I explore T1 in ATTR in chapter 11.
There are three problems with native T1 mapping: firstly conceptually, it measures a
composite myocardial signal from both interstitium and myocytes. Secondly, it does not
differentiate fully the underlying processes – particularly oedema and amyloid (though it is
not impossible that that oedema may form part of the spectrum of myocardial amyloid
infiltration) and thirdly, different CMR systems and sequences have different normal
ranges. Standardization is only now starting – but consensus guidelines (67) are now
available. Normal T1s are higher when measured at 3T (68), with different sequences
(“SASHA” compared to other techniques), and typically with newer variants of mapping
compared to older ones (69). Current recommendations are for normal reference ranges to
be defined locally, but this may change over time.
The use of gadolinium-chelated contrast agents adds another dimension to CMR
tissue characterization with T1 mapping. Post-contrast T1 may be lower in cardiac disease
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suggesting increased myocardial interstitial space. However, care is needed as the
disease may have altered body composition (a higher percentage of body fat and, thus, a
greater contrast dose per unit of total body extra-cellular water), reduced renal function, or
altered haematocrit. The fraction of tissue that is interstitial space is referred to as the
extracellular volume (ECV). It can be calculated from the ratio of signal change in blood
and myocardium after contrast administration and the blood contrast volume of distribution
(equal to one minus haematocrit) (figure 7).
Figure 7. T1 maps, LGE and ECV maps of a patient with aortic stenosis and a patients with
cardiac amyloidosis.
A patient with left ventricular hypertrophy from aortic stenosis (upper panels) and cardiac
amyloidosis (lower panels). From left to right: T1 maps pre-contrast (left), post-contrast centre left,
LGE centre right and extracellular volume (ECV) maps right. In the patient with cardiac amyloidosis
on the ECV maps there is evidence of massive interstitial volume expansion with ECV elevation.
Amyloidosis is the exemplar of interstitial disease, and this is reflected by massive
ECV elevation in the patients with definite AL cardiac amyloidosis (65,70). ECV is
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elevated also in AL patients where conventional clinical testing and LGE suggested no
cardiac involvement, highlighting a potential role as early disease marker (65).
ECV appears to be more robust between centres and approaches, being a ratio of
change compared to T1. Furthermore high global ECVs can become very specific: fibrosis
cannot achieve remote (non-infarct) ECVs of above ~0.4, implying that an ECV value
greater than ~0.4 in remote myocardium become highly specific, with the only other
differential being global oedema – a newly reported but not well understood phenomenon.
Combined, native T1 mapping and ECV measurement could therefore over time add
insight into cardiac amyloidosis at 3 different levels, i.e. infiltration (amyloid burden, ECV),
oedema (native T1) and myocyte response (intracellular volume), providing a richer
understanding of the pathophysiological mechanism. These hypotheses are derived from
my work in chapter 10.
Diagnostic utility: CMR adds value to the certainty of probable amyloidosis patients. In
the UK, where CMR is a well-developed national service, it has impacted referral patterns
with a large national increase in the identification of patients with ATTR cardiac
amyloidosis, particularly wild type, constraining resources in existing amyloid centres.
Prospective studies with the aim of comparing the diagnostic accuracy of CMR against
other approaches have not been done yet, but there are pointers.
. CMR adds value to the Mayo classification (or its equivalent in ATTR), and LGE
can be pathognomonic of amyloidosis (but less so of specific subtype). CMR findings
have increased accuracy compared to conventional echocardiographic imaging both in
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terms of specificity and sensitivity: for example HCM may share features such as
concentric hypertrophy, bi-atrial dilatation, reduced longitudinal function(72,73) and
decompensated biventricular restrictive disease (74) but both HCM and amyloid may have
unique tissue characterisation findings (54,58,75), but difficulties persist because of the
variable pattern of LGE.
Native myocardial T1 can be used to support the diagnosis or exclusion of AL
cardiac amyloidosis. This can be done choosing different cut-offs, based on the clinical
scenario, with specificity and sensitivity to diagnose or exclude cardiac amyloidosis
respectively. Ideally, the native T1 on subjects with end stage renal failure should be
known as the comparator (rather than just healthy subjects), but this is not well studied at
this time.
CMR methods to distinguish types of cardiac amyloidosis: Structural findings related to
hypertrophy and functional characteristics differ according to amyloid sub-type.
Transthyretin amyloid usually manifests as disproportionately increased LV mass and
interventricular septal thickness, larger atrial area, smaller cavity volumes and lower
ejection fraction (within the normal range) than AL amyloid (58), despite similar NYHA
class and NT-proBNP levels.
Tissue characteristics can be different in the different amyloid subtypes. The pattern
and extent of LGE differs in ATTR and AL amyloidosis, with LGE typically more extensive
in ATTR than AL patients, but (chapter 11), this may be a survivor bias – with transmural
LGE in AL associated with swift death. RV LGE appears to be present in most ATTR
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amyloid cases, but in only a majority with AL amyloid. A semi-quantitative LGE score
combined with age and myocardial wall thickness had a reported sensitivity of 87% and
specificity of 96% for distinguishing ATTR from AL amyloid (58). Caveats to this score
were the non-standardized approach used in the validation cohort of a retrospective study,
use of different contrast agents, doses, acquisition times and LGE sequences which are all
factors that have the potential to affect LGE patterns.
Prognostic ability: Presence of LGE is predictive of prognosis in virtually all the
cardiac pathologies, except for amyloidosis where studies have conflicting results and
have been small and in AL only with non-standardized LGE approaches (52,54,55,76). As
discussed above, the LGE can be problematic in amyloid with global infiltration and altered
wash-in and wash-out kinetics. Specifically, patients exhibiting the most advanced
interstitial infiltration can occasionally be portrayed as having no LGE (figure 6) – a
misclassification that profoundly confounds prognostic studies. PSIR-LGE approach has
the potential to shed light on this, clarifying the role of LGE in the stratification of patients
with AL and ATTR cardiac amyloidosis.
Measurement of native myocardial T1 and ECV aids risk-stratifying patients with AL
cardiac amyloidosis (77) (Figure 8).
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Figure 8. Kaplan Meier survival curves for native T1 and ECV in AL amyloidosis.
(A) Native myocardial T1 and (B)Extracellular volume (ECVb). Adapted from Banypersad SM et
al.(77)
This probably adds incremental value over and above existing clinical markers, although
the published multivariable analyses are somewhat strained. More certainly, T1 and ECV
add value when conventional parameters are confounded – e.g. blood biomarkers in renal
failure, mild LVH in hypertension. Incremental value appears present regardless of
treatment status and whether newly presenting or under established follow-up; ATTR
amyloidosis data is awaited. The use of these biomarkers to guide or tailor therapy and
monitor response has not been explored yet.
Surrogate endpoints in drug development: Disease tracking is a fundamental step for
drug development – the detection of biological effect (beneficial and off target) and dose
ranging. No imaging modality has been shown to track changes over time in patients with
cardiac amyloidosis, particularly away from “end-stage” diseases, but T1 mapping has
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high potential. LV mass changes are a poor target endpoint as mass consists of myocyte
volume (beneficial) and infiltration volume (adverse), and changes over time are not large
compared to measurement error. Changes in function (stroke volume index rather than
EF) have similar problems, with the additional confounder of deterioration in function
associated with occurrence of atrial fibrillation rather than disease progression. T1
mapping, has the potential to track structural changes over time at 3 different levels, i.e.
infiltration (amyloid burden, ECV), possibly oedema (native T1) and myocyte response
(intracellular volume), providing a richer understanding of the pathophysiological of the
response to treatment (78,79) – hypotheses from chapter 10. ECV quantification has
however been considered sufficiently robust to be used (by my centre, myself leading) in
several early phase drug development studies.
6.6AMYLOID TREATMENTS
Cardiac amyloidosis in general has a poor prognosis, but this differs according to
amyloid type, and availability and response to therapy. Treatment may be “amyloid-
specific” or “non amyloid-specific” as detailed below:
6.6.1 AMYLOID NON-SPECIFIC TREATMENTS
Heart failure treatment – Standard heart failure therapy may be of limited benefit or
even detrimental in cardiac amyloidosis. There is scanty evidence for the use (or not) of
ACE-i, ARBs and β blockers.  These may be poorly tolerated, worsen postural 
hypotension or renal function (ACE/ARBs). Restrictive cardiomyopathy leads to a heart-
rate dependent cardiac output in some cases and such patients may find difficulty in
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tolerating beta-blockers. Digitalis and calcium channel blockers may be selectively
concentrated in amyloidotic tissue and are relatively contraindicated on grounds of
increased toxicity (80-82) especially the latter, which can lead to rapid worsening.
Device therapy – Pacemakers or implantable cardioverter-defibrillators (ICDs) may
not prevent sudden cardiac death, since this is thought to often be due to
electromechanical dissociation.(83,84) In the absence of evidence, pacing indications
remain within current standard guidelines. High defibrillator thresholds may be
encountered and the benefits of such devices remain uncertain.(83) (85,86) Biventricular
pacing appears to play little role. (87)
Cardiac transplantation – Cardiac transplantation has played a disappointingly small
role, due to the multisystem nature of amyloidosis, advanced age, treatment related
complications, and rapid disease progression. As a result, only a few dozen cardiac
transplants have ever been performed for amyloidosis. However, the long-term outcome
can be good in highly-selected patients with AL amyloidosis.(88) Cardiac transplantation
followed by successful peripheral blood autologous stem cell transplant (ASCT) was
associated with better survival in selected patients as reported (89) from most major
amyloidosis units in the UK,(88) France,(90) Germany(91) and the USA.(92) For variant
ATTR, combined cardiac and liver transplantation has been performed in a few dozen
cases throughout the world.(88,89,93,94)
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6.6.2 AMYLOID SPECIFIC TREATMENTS
Reducing amyloid fibril precursor protein production – Treatment is currently based on the
concept of reducing the supply of the respective amyloid fibril precursor protein.
In AL amyloidosis, therapy is directed towards the clonal plasma cells. Achieving a
haematological response in AL amyloidosis translates into improved overall survival and
complete haematologic responses (CR; defined as a normal ratio of κ to λ FLC in the 
serum and negative serum and urine immunofixation) and very good partial haematologic
responses (VGPR; defined as difference in level of involved and uninvolved FLC [dFLC]
<40 mg/l) are associated with the best clinical outcomes(42,95). A new paradigm for the
treatment of AL amyloidosis has been proposed in which the underlying haematologic
disorder and the end-organ damage should be monitored using FLC assays and cardiac
biomarkers, respectively, to optimize therapy and minimize toxicity.(96) Treatment
regimens for AL amyloidosis are administered by haematologists and were adapted from
regimens that were developed for multiple myeloma, although most patients with AL
amyloidosis have a low-grade plasma cell dyscrasia and small clonal burden. Treatment
for AL amyloidosis is based on age, regimen toxicities and cardiac involvement that
currently is based on Troponin and brain natriuretic peptide levels (97). Outcomes in
patients with AL amyloidosis have improved following the introduction of effective
chemotherapy regimens.
Currently, the treatment regimens that are most widely used to treat AL amyloidosis
include combinations that contain bortezomib (cyclophosphamide, bortezomib and
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dexamethasone), melphalan (melphalan and dexamethasone), thalidomide
(cyclophosphamide, thalidomide and dexamethasone) and lenalidomide (lenalidomide and
dexamethasone). High-dose melphalan in combination with autologous stem cell
transplantation is associated with excellent clinical outcomes,(98,99) but rigorous selection
of suitable patients is required owing to the excessive risk of treatment-related mortality in
certain individuals with AL amyloidosis, particularly those with substantial cardiac or
autonomic nerve involvement.(100)
ATTR is produced almost exclusively in the liver. Liver transplantation has been
used as a treatment for variant ATTR for 20 years, to remove genetically variant TTR from
the plasma. Although this is a successful approach in ATTR Val30Met, it has had
disappointing results in patients with other ATTR variants which often involve the heart.
The procedure commonly results in progressive cardiac amyloidosis through on-going
accumulation of wild-type TTR on the existing template of variant TTR amyloid.(101) The
role of liver transplantation in non-Val30Met associated hereditary TTR amyloidosis thus
remains very uncertain. Exercise training post-surgery can be helpful however.(102)
ATTR amyloidosis has lately become a focus for novel drug developments aimed at
reducing production of TTR through silencing RNA and antisense oligonucleotide
therapies (103) (104,105).
Inhibition of amyloid formation – Amyloid fibril formation involves massive
conformational transformation of the respective precursor protein into a completely
different form with a predominantly β-pleated sheet structure.  The hypothesis that this 
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conversion might be inhibited by stabilising the fibril precursor protein through specific
binding to a pharmaceutical product has lately been explored in ATTR amyloidosis. A key
step in TTR amyloid fibril formation is the dissociation of the normal TTR tetramer into a
monomeric species that can auto-aggregate into a misfolded form. In vitro studies
identified that diflunisal, a non-steroidal anti-inflammatory analgesic bound by TTR in
plasma, enhances the stability of the normal soluble structure of the protein.(106,107)
Preliminary clinical data showed that diflunisal may reduce the rate of neurological
impairment and preserve quality of life in patients with FAP.(108)
Tafamidis is a compound without anti-inflammatory analgesic properties that has a
similar mechanism of action. Tafamidis has been licensed for neuropathic ATTR but its
role in cardiac amyloidosis remains uncertain.(109) Higher affinity ‘superstabilizers’ are
also in development.(110)
Targeting Amyloid Deposits – Amyloid deposits are remarkably stable, but the body
evidently has some limited capacity to remove them. Following treatment that prevents
the production of new amyloid, e.g. successful chemotherapy in AL type, amyloid deposits
are gradually mobilised in the majority of patients, though at different rates in different
organs and between individuals. Unfortunately clearance of amyloid is especially slow in
the heart, and echocardiographic evidence of improvement is rare, even over years.
The challenge of developing a therapeutic monoclonal antibody that is reactive with
all types of amyloidosis is currently being addressed by targeting SAP, since this is a
universal constituent of all amyloid deposits and an excellent immunogen. Anti-SAP
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antibody treatment is clinically feasible because circulating human SAP can be depleted in
patients by the bis-d-proline compound CPHPC, thereby enabling injected anti-SAP
antibodies to reach residual SAP in the amyloid deposits (Figure 9).(111) The
unprecedented capacity of this novel combined therapy to eliminate amyloid deposits in
our phase I study recently published in NEJM is encouraging and seems be applicable to
all forms of human systemic and local amyloidosis(112).
Figure 9. CPHPC, SAP and anti-SAP antibody.
Showing (A) cross-linking of SAP by CPHPC molecule; (B) Circulating SAP in a patient with
amyloidosis, showing the normal level of “coating” of amyloidotic organs by SAP and baseline low-
level sequestration of circulating SAP by the liver; (C) Addition of CPHPC causing cross-linking of
SAP in the blood and subsequent high level excretion of SAP from blood by the liver; (D) Addition
of the anti-SAP antibody causing removal of SAP coating from amyloidotic organs, allowing
immune system to destroy the amyloid in the target organ. Picture courtesy of Dr Duncan
Richards, GSK.
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7. RESEARCH AIMS
This thesis investigates the use and development of novel CMR methods to improve the
diagnostic accuracy, risk stratification and gain pathophysiology insights in amyloidosis.
This thesis is built on the work of others – key methods were developed at Heart Hospital
by my colleagues: (a) Dr Andrew Flett (UCL MD (Res), 2012) who designed and validated
EQ-CMR (Equilibrium contrast CMR) to measure myocardial fibrosis in aortic stenosis and
HCM; (b) Dr. Daniel Sado (UCL MD (Res), 2013) who explored ECV (again for fibrosis)
across a variety of cardiac diseases; (c) Dr. Sanjay Banypersad (UCL MD (Res), 2015)
who explored ECV (here for amyloid burden) for the investigation of the extracellular space
of heart, liver and spleen in AL amyloidosis. My thesis built on these.
My aims were:
1- Methodology: Improve the technique currently used to measure ECV with the use of
newer, faster sequences (ShMOLLI) to measure the extracellular volume.
2- To assess the diagnostic accuracy of non-contrast techniques (native T1) to detect
cardiac involvement in ATTR amyloidosis.
3- Improve the understanding of the pathophysiology of the disease: understand the
myocardial response to amyloid: is there cell hypertrophy or cell loss in response to
amyloid infiltration? Is the myocyte response different in AL and ATTR?
4- Deliver a test suitable for use in clinical practice: to explore the potential of a widely
available technique (LGE PSIR approach) to improve risk stratification of patients
with cardiac amyloidosis.
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8. MATERIAL AND METHODS
8.1 ETHICAL APPROVAL
All ethics were approved by the UCL/UCLH Joint Committees on the Ethics of Human
Research Committee, and all participants provided written informed consent.
8.2 PATIENTS
PATIENTS WITH AL AND ATTR AMYLOIDOSIS
A total of 250 consecutive patients were scanned from the NAC over the course of
3 years. These patients were usually attending the NAC for a 24 or 32 hour period in order
to have ECG, echo, SAP scan and a clinical consultation. All CMR scans were performed
at the Heart Hospital and it was therefore necessary to transport patients from the NAC to
the Heart Hospital and back in between their other numerous investigations. This was a
limitation of the recruitment process.
Patients were categorized as follows:
 AL 119
 ATTR 122
 Mutation carriers 9
Before having their CMR scan, AL patients were sub grouped into their pre-test
probability of having cardiac involvement as follows: (113)
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Definite cardiac involvement – any of:
 Left ventricular wall thickness of ≥12mm by echocardiography in the absence of any 
other known cause
 RV free wall thickening co-existing with LV thickening by echocardiography in the
absence of systemic or pulmonary hypertension
Possible cardiac involvement – any of:
 LV wall thickening by echocardiography in the presence of hypertension
 RV thickening by echocardiography in the presence of pulmonary hypertension
 Normal wall thickness by echocardiography with diastolic dysfunction and raised serum
biomarkers (7)
No suspected involvement
 Normal wall thickness by echocardiography with normal serum biomarkers
Before having their CMR scan, ATTR patients were sub grouped into their pre-test
probability of having cardiac involvement as follows:
Definite cardiac involvement – any of:
 cardiac biopsy showing ATTR amyloid;
 non-cardiac biopsy showing ATTR amyloid in association with left ventricular/right
ventricular thickening in the absence of other explanatory causes;
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 intense DPD uptake in heart (grade 2 or 3 as defined by Perugini et al) in the absence
of a plasma cell dyscrasia;(47)
 non-cardiac biopsy showing presence of ATTR amyloid and LGE consistent with
cardiac amyloid - In practice, all had apparent left ventricular hypertrophy (LVH).
Possible cardiac involvement:
 minimal cardiac DPD uptake (grade 1 as defined by Perugini et al(47) in the
absence of LVH – in practices, none of these had LVH.
No suspected involvement:
 Normal wall thickness by echocardiography with normal serum biomarkers and no
cardiac uptake on DPD.
HEALTHY VOLUNTEERS AND OTHER DISEASE COHORT
65 normal subjects were recruited through advertising within the hospital, university
and general practitioner surgeries. All normal subjects had no history or symptoms of
cardiovascular disease or diabetes. Four subjects had been prescribed statin therapy for
hypercholesterolaemia (primary cardiovascular prevention), but no other normal subject
was taking any cardiovascular medication. All subjects had a normal blood pressure, 12
lead electrocardiogram and clinical CMR scan.
Patients with HCM (n=46) or aortic stenosis (AS) (n=18) were prospectively
recruited from tertiary clinical and research departments at the Heart Hospital or the
National Amyloidosis Centre, Royal Free Hospital.
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These scans (healthy individuals, HCM and AS) were performed and reported by
Dr. Daniel Sado, Dr. Viviana Maestrini and Dr Steve White as a comparator group for ECV
studies within our group.
8.3 CARDIOVASCULAR MAGNETIC RESONANCE PROTOCOL
All scans were performed on a 1.5 Tesla Siemens™ Avanto scanner and images
always acquired during breath-hold at end expiration.
PILOT IMAGES:
All studies started with single shot pilot images with the following settings: repeat
time (TR): 3.39ms, echo time (TE): 1.7ms, slice thickness, 5mm, field of view (FOV) 360 x
360mm, read matrix 256 and flip angle 60o.
CINE IMAGES:
After piloting, steady state free precession (SSFP) cine imaging was then
undertaken, firstly in the long axis planes with a short axis cut through the aortic valve. A
standard LV short axis stack was then acquired using a slice thickness of 7mm with a gap
of 3mm. Retrospective ECG gating was used with 25 phases. Typical fast imaging with
steady state precession (FISP) imaging parameters were TE: 1.6ms, TR: 3.2 ms, in plane
pixel size 2.3 x 1.4mm, slice thickness 7mm, flip angle 60. These settings were optimised
accordingly if the subject was unable to breath-hold, or had an arrhythmia etc..
54
T1 AND ECV MEASUREMENT
T1 measurement pre-contrast was performed using:
(a) FLASH-IR (in 100 subjects, 50 healthy volunteers and 50 patients, see chapter
number 8) at increasing inversion times from 140 to 800ms (or 900ms if patient heart rate
permitted), “multibreath-hold technique”.
(b) ShMOLLI T1 mapping “single breath-hold technique”, (in all patients). After a bolus of
Gadoterate meglumine, (0.1 mmol/kg, gadolinium-DOTA, marketed as Dotarem © Guerbet
S.A. France) and standard LGE imaging, at 15-minute post bolus, an infusion at a rate of
0.0011 mmol/kg/min contrast (equivalent to 0.1 mmol/kg over 90 minutes) was given. The
patient was typically removed from the scanner at this time. At between 45 minutes and 80
minutes post bolus, the patient was returned to the scanner, still with the infusion, and the
T1 measurement repeated using both multi and single breath-hold techniques. Separate
regions of interest (ROIs) were placed in all available images and recovery curve was
reconstructed by fitting the relaxation formula to ROI averages. Heart rate correction was
used for the multibreath-hold technique (9). In the ShMOLLI sequence, T1 maps were
generated using previously published algorithm (12). A single ROI was drawn directly in
each T1 map at the same location as the multibreath-hold technique and T1 averaged
between all pixels. T1 was measured in the basal to mid septum avoiding areas of late
gadolinium enhancement, except in myocardial infarction (where the infarct zone was
assessed) and amyloid (where the regions was drawn irrespective of the ill-defined
55
presence/absence of LGE). The blood T1 was assessed in the descending aorta. All the
analysis were performed blinded.
A single ROI was drawn directly in the septum in each 4 chamber T1 map performed prior
to contrast administration and at equilibrium. A haematocrit was taken in all subjects on
the same day. Five different parameters were calculated (114):
1- Native myocardial T1
2- ECV = (1 - haematocrit) x (ΔR1myocardium / ΔR1 blood)
3- ICV= 1 - ECV
4- Total Amyloid Volume = ECV x LVmassi
5- Total Cell Volume = ICV x LVmassi
For test:retest interstudy reproducibility, 10 normal subjects and 7 patients with amyloid
underwent repeat scanning, one week apart. The analysis was carried out by a single
observer blinded.
LGE IMAGING
Intravenous Gadoterate meglumine (gadolinium-DOTA, marketed as Dotarem®
Guerbet, S.A., France) was then administered as a 0.1mmol/kg dose via a pressure
injector at a rate of 3ml/sec, with a 25ml normal saline flush. LGE assessment was then
undertaken using a FLASH IR sequence. Magnitude reconstruction was available in all
patients (MAG-IR) phase sensitive inversion recovery sequences (PSIR) reconstructions
the later 43% of patients. Slice thickness 8 mm, TR: 9.8 ms, TE: 4.6ms, α: 21o, FOV 340 x
220 mm (transverse plane), sampled matrix size 256 x 115-135, 21 k–space lines acquired
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every other RR interval (21 segments with linear reordered phase encoding), spatial
resolution 1.3 x 2.1 x 8 mm, no parallel imaging, pre-saturation bands over CSF and any
pleural effusions.
These parameters were optimised according to individual patient characteristics.
The TI was manually set to achieve nulling of the myocardium between 300 and 440 ms.
When LGE was observed, images were acquired in phase swap and cross cut to ensure
artefact elimination. Where the LGE distribution appeared particularly diffuse, a TI scout
was used to ascertain the specific parts of myocardium with the highest concentration of
gadolinium. If the participant was struggling with the breath-hold, FISP imaging or IR-
SSFP imaging (single shot or segmented) was used as an alternative sequence.
8.4BLOOD PRESSURE AND 12 LEAD ECG
All patients had their blood pressure (BP) measured at the National Amyloidosis
Centre on a CareScape™ V100 machine by the nursing staff as part of their routine
workup. In the healthy volunteer cohort, BP was measured after their CMR scan by Dr.
Daniel Sado and Dr. Viviana Maestrini using a Mindray™ machine.
A 12 lead ECG was performed on all patients at the National Amyloidosis Centre on
the same day as the CMR scan, as part of their clinical work up. The ECG was acquired
using a calibration of 10 mm/mV and speed of 25 mm/s. Interpretation of the trace was
performed by myself. Healthy volunteers followed an identical protocol.
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8.5BLOOD TESTS
All participants had blood tests taken prior to the CMR scan at the National
Amyloidosis Centre as part of their clinical workup. This included NT-proBNP and serum
free light chain in all cases, with Troponin T in just over half the cases as this is only
routinely performed on new patients.
8.6SIX MINUTE WALKING TEST (6MWT)
This was performed at the Heart Hospital (where the test was originally developed)
along a flat corridor in accordance with current guidelines.(115) Patients were asked to
walk a 30-metre length of the corridor at their own pace while attempting to cover as much
ground as possible in the 6-minute period. Verbal encouragement was given using either
of 2 standardised phrases: ‘‘You are doing well’’ or ‘‘Keep up the good walk.’’ At the end of
6 minutes, participants were asked to stop and the distance covered was recorded. Any
symptoms were recorded, as was the Borg score (on a scale of 1-10) to assess the degree
of breathlessness.(116)
7.8 ECHOCARDIOGRAPHY
In all patients, transthoracic echocardiography was performed at the National
Amyloidosis Centre on a Philips® IE33 machine as a part of the routine clinical work up.
Echo studies, included tissue doppler just above the mitral valve annulus at the septal and
left ventricular lateral wall. Scans were performed and analysed by 2 echocardiographers
experienced in scanning patients with cardiac amyloidosis. Accepted markers of diastolic
dysfunction i.e. isovolumic relaxation time (IVRT), E-deceleration time and E:E’ ratio were
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all measured.(117) Echocardiography was not used to assess left ventricular systolic
function for this work, as CMR was seen as the gold standard in this regard.(118)
7.10 DPD SCINTIGRAPHY
Most of the ATTR patients had DPD scans (instead of SAP scans) by the time of their
appointment though this was not always possible because of time and scanner limitations
on the day. Where performed, Patients were scanned using two General Electric (GE)
Medical Systems hybrid SPECT-CT gamma cameras (Infinia Hawkeye 4 and Discovery
670) following administration of 700 MBq of intravenously injected 99mTc-DPD.Three hour
(delayed) whole body planar images were acquired followed by a single photon emission
computed tomography (SPECT) of the heart with a low-dose, non-contrast CT
scan. Gated/non-gated cardiac SPECT reconstruction and SPECT-CT image fusion was
performed on the GE Xeleris workstation. Cardiac retention of 99mTc-DPD was visually
scored as: Grade 0 - no visible myocardial uptake in both the delayed planar or cardiac
SPECT-CT scan; Grade 1 - cardiac uptake on SPECT-CT only or cardiac uptake of less
intensity than the accompanying normal bone distribution; Grade 2 – moderate cardiac
uptake with some attenuation of bone signal; and Grade 3 – strong cardiac uptake with
little or no bone uptake.
7.11 STATISTICAL ANALYSIS
Statistical analysis was performed using IBM SPSS Statistics Version 19 (IBM, Somers,
New York) and R programming language (available at http://www.r-project.org/).
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All continuous variables were normally distributed (Shapiro-Wilk), other than NT-proBNP
and Troponin T which were therefore log transformed; these are presented as mean ±
standard deviation (SD) (non-transformed NT-proBNP as median and interquartile range).
Comparisons between groups were performed by 1-way analysis of variance with post-
hoc-Bonferroni correction. The chi-square test or Fisher exact test was used to compare
discrete data as appropriate. Receiver-operating characteristic (ROC) curve analysis was
performed to define the diagnostic accuracy of native T1. Correlations between were
assessed using Pearson (r) or Spearman’s rho.
We used Intraclass Correlation Coefficient (ICC) and Bland-Altman plot to compare ECV
values from the two methods. Interstudy reproducibility for ECV was assessed by
calculating the ICC and Bland Altman plots. To compare the squared difference of paired
ECV measurements Wilcoxon signed rank test was used. To assess the agreement of the
assignment of the LGE pattern by two different observes, ICC was calculated.
Survival was evaluated using Cox proportional hazards regression analysis, providing
estimated hazard ratios (HR) with 95% confidence intervals (CI) and Kaplan Meier curves.
Variables selected a priori for the clinical relevance and first explored with univariate Cox
regression were entered in the multivariable models. Multivariable models evaluated the
independent predictive value of LGE above other clinically and statistically significant
covariates. Harrell’s C statistic was calculated for the different models.
A p value <0.05 was considered statistically significant.
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9. RESULTS: COMPARISON OF T1 MAPPING TECHNIQUES FOR ECV
QUANTIFICATION
This chapter is based on the publication below:
Fontana M, White SK, Banypersad SM, Sado DM, Maestrini V, Flett AS, Piechnik SK, Neubauer S,
Roberts N, Moon JC. Comparison of T1 mapping techniques for ECV quantification. Histological
validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium
contrast CMR. J Cardiovasc Magn Reson. 2012;14:88.
My contribution was analysing all the data as first operator, doing the statistical analysis and
writing the paper.
9.1 INTRODUCTION
ECV can be measured non-invasively by CMR using pre and post contrast T1 relaxation
times of blood and myocardium (the latter at sufficient contrast equilibrium) with correction
for the blood volume of distribution via the haematocrit. (119,120) A number of T1
measurement techniques exist including multibreath-hold techniques such fast low angle
single shot inversion recovery (“multibreath-hold FLASH-IR”). Here the sequence is
performed at increasing inversion times to generate T1 recovery curves and heart rate
correction.(121,122) Newer, faster sequences such as MOLLI (Modified Look-Locker
Inversion recovery)(123) perform IR measurements in a single breath-hold. A recent
evolution of MOLLI, the Shortened-MOLLI (ShMOLLI) (124) improves clinical utility with a
shorter breath-hold and immediate map reconstruction directly on the scanner. ECV
measurements have been performed and validated using MOLLI for bolus-only protocols.
Equilibrium contrast CMR (EQ-CMR) with single breath-hold sequences has not yet been
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validated for ECV assessment. ECV mapping with such sequences would be a significant
technical advance, being easier for patients with shorter breath-holds (either shorter scans
or whole heart coverage) and easier quantification.
9.2HYPOTHESIS
We hypothesised that ECV mapping using ShMOLLI would be superior to the multibreath-
hold FLASH-IR technique. This was assessed in three ways: firstly, to determine any bias
in ECV between the two techniques. Secondly, we compared both CMR techniques with
histological collagen volume fraction (CVF%). Finally, we assessed the reproducibility of
both CMR techniques. For equivalence of contrast conditions between the two
techniques, we used the primed infusion technique, equilibrium contrast CMR.
9.3 MATERIALS AND METHODS
CMR PROTOCOL
After ethical approval, subjects underwent CMR as described in the methods. For this
study, T1 measurement pre-contrast was performed using (a) FLASH-IR at increasing
inversion times from 140 to 800ms (or 900ms if patient heart rate permitted), “multibreath-
hold technique”, Figure 10a and (b) ShMOLLI T1 mapping “single breath-hold technique”,
Figure 10b. After a bolus of Gadoterate meglumine, (0.1 mmol/kg, gadolinium-DOTA,
marketed as Dotarem © Guerbet S.A. France) and standard LGE imaging, at 15-minute
post bolus, EQ-CMR was performed as described in the methods. A single ROI was drawn
directly in each T1 map at the same location as the multibreath-hold technique and T1
averaged between all pixels (Figure 10b) and ECV was calculated as described in the
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methods.
Figure 10. Native T1 measurement example.
Left multiple panels: the multibreath-hold T1 measurement uses up to 7 CMR acquisitions with
linearly increasing inversion time. T1 value is reconstructed from fitting average signal intensity
from individual image intensity averages. Right single panel: ShMOLLI technique generates T1
map directly on the scanner console using pixelwise calculations based on a single breath-hold
experiment. ShMOLLI T1 is calculated as average of all pixels from a region of interest drawn in
the myocardium.
PATIENT STUDIES: HEALTHY NORMAL SUBJECTS AND DISEASE GROUPS
Normal subjects (n=50, median age 47±17, 53% male) were recruited. Patients (n=50)
were: (1) 12 patients with HCM meeting the diagnostic criteria (average age 52±13, 60%
male). (2) 18 patients with severe aortic stenosis waiting for aortic valve replacement
(median age: 71±10, 72% male). (3) 20 patients with cardiac AL amyloidosis with disease
proven by non-cardiac biopsy and cardiac involvement ascertained through
echocardiography, supported by a Mayo clinic classification score of 2 or 3 (average age:
60±10, 75% male). Patients with atrial fibrillation or a contra-indication to contrast CMR
examination were excluded.
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HISTOLOGICAL VALIDATION
24 patients with severe aortic stenosis listed for surgical aortic valve replacement were
studied. An intraoperative deep myocardial biopsy (Tru-Cut needle) was taken in aortic
stenosis. Samples were stained and analysed for CVF%, as previously described.(121) 6
patients were excluded (2 patients had focal fibrosis detected as LGE in the basal septum;
2 patients had biopsies consisting solely of endocardial fibrosis; in 1 patient multibreath-
hold T1 quantification was not performed because the patient was unable to breath-hold; 1
patient had a pulmonary oedema during the scan) leaving 18 patients.
REPRODUCIBILITY
For test:retest interstudy reproducibility, 10 normal subjects and 7 patients with amyloid
underwent repeat scanning, one week apart. The analysis was carried out by a single
observer blinded.
DATA ANALYSIS AND STATISTICS
Intraclass Correlation Coefficient (ICC) and Bland-Altman plot compared ECV values from
the two methods and Interstudy reproducibility. To compare the squared difference of
paired ECV measurements Wilcoxon signed rank test was used.
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9.4 RESULTS
ECV COMPARISON
No patients failed ShMOLLI acquisition. 6% of patients were unable to perform all the 14
breath-holds required for the multibreath-hold technique. The mean ECV assessed using
multibreath-hold T1 quantification and ShMOLLI T1 in normal subjects and disease groups
is shown in table 1. ECV by multibreath-hold T1 quantification and by ShMOLLI T1
mapping showed excellent correlation (r2=0.892) and agreement across disease groups
(overall ICC 0.922, 95% CI 0.802 to 0.961, p<0.0001), figure 11a, with little bias on Bland
Altman (bias -2.2%, 95%CI -8.9% to 4.6%), figure 11b.
Table 1. Multibreath-old T1 and ShMOLLI T1 in normal subjects and disease groups.
Figure 11. Sh-MOLLI and multibreath-hold ECV correlation and Bland-Altman.
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Sh-MOLLI and multibreath-hold ECV correlation in health and disease (panel a) and the same data
plotted as a Bland-Altman analysis (panel b), showing little bias.
HISTOLOGICAL VALIDATION
All biopsies were uneventful. The mean histological CVF of the 18 biopsies was 18% ± 8%
(range 7% to 40%). There was a strong correlation between histological CVF% and
FLASH ECV (r2= 0.589) but this was stronger with ShMOLLI ECV (r2= 0.685) (Figure 12).
Figure 12. Extracellular volume (ECV) against collagen volume fraction (CVF%).
ECV against histological CVF% (n=18) by ShMOLLI (panel a) and multi-breath-hold (panel b).
INTERSTUDY REPRODUCIBILITY
ShMOLLI ECV was slightly more reproducible than the multibreath-hold ECV, Figure 13,
(ICC 982, 95%CI 0.951-0.994 versus ICC 962, 95%CI 0.897-0.987), with narrower
confidence intervals (95%CI -4.9% to 5.4% versus 95%CI -6.4% to 7.3% respectively).
Neither of these reached statistical significance however , P>0.2.
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Figure 13. Bland-Altman: T1 values using FLASH-IR and ShMOLLI.
Bland-Altman analysis to express the intrasequence reproducibility of the myocardial T1 values
using FLASH-IR (panel a) and ShMOLLI (panel b) in normal subjects (blu square) and amyloid
patients (orange square). The limits of agreement are slightly narrower for ShMOLLI than
multibreath-hold.
9.5DISCUSSION
CMR ECV quantification requires accurate and rapid T1 relaxation time calculation. We
have found that ShMOLLI compared to multibreath-hold T1 quantification has a greater
chance of technical success on all patients, less bias over a wide range of ECV
measurements, a higher correlation with histological CVF% as well as better
reproducibility. These four findings combine with key advantages of the mapping
technique: a single breath-hold per T1 map, simple analysis and the potential for whole
heart ECV quantification. Therefore, it is our opinion that T1 mapping technique ShMOLLI
is the superior CMR technique for ECV quantification.
T1 mapping by means of the multi-breath-hold technique is one of the most commonly
utilised methods for T1 quantification.(121,122) The main advantage of this technique is
that it is not vendor specific and it has been heavily optimised by everyday clinical practice
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to obtain high resolution LGE images. However it also has a number of limitations. Firstly,
in order to map a single cardiac slice, it requires the sequence to be run up to 9 times at
increasing inversion times. The average breath-hold time for each sequence is 14 seconds
(longer at slower heart rates). If the patient cannot hold their breath for the duration of the
sequence, artefact will appear on any one of the images. This may also occur if the patient
has an arrhythmia. As each slice takes so many breath-holds to map, this method can not
be used clinically for whole heart mapping (i.e. of multiple cardiac slices). Once the images
have been obtained, the offline post processing is laborious and the results require heart
rate correction for the calculated T1 relaxations times.(121)
We have found that ECV quantification using ShMOLLI improves on several practical
aspects compared to multibreath-hold T1 quantification. ShMOLLI imaging is
characterised by lower breath-hold failure rate, less bias over a wide range of ECV, a
slightly higher correlation with histological collagen volume fraction and slightly better
reproducibility, although it does not reach statistical significance. Shorter acquisition times
and direct T1 map calculation on the scanner (124) ensures ShMOLLI is quicker to
perform and analyse with a potential to provide whole heart ECV quantification. While
currently ShMOLLI is (was) vendor specific, its predecessor MOLLI exists for more than
one platform (126)(13).
Future techniques for T1 measurement are likely to be based on mapping. Further
advances may include higher resolution imaging with reduction of partial volume effects,
with that incorporate motion correction and improved capabilities for measuring longer
T1s.(127-130) We preferred here to re-iterate the T1 map for maximum accuracy – a step
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that will likely be un-necessary in future refinements. Preliminary exploration is being made
of combining the two T1 maps into an ECV map using further non-rigid registration.(122)
This study has limitations. We have not presented the phantom work comparing ShMOLLI
and FLASH-IR T1 estimation as this was primarily an ECV clinically-orientated paper with
many of the likely confounders present only in-vivo and not detectable by phantom work.
Histology correlations were lower than previously described.(121) We believe this is
primarily due to different population characteristics (the population examined here is older)
and to a greater number of surgeons involved in the biopsy arm of this study (with
associated reduced homogeneity of samples). Finally, FLASH-IR was compared to a
single T1 mapping technique, ShMOLLI. MOLLI, its variants and other T1 mapping
techniques were not considered in this study.
As ECV quantification experience increases, technology will advance to become more
precise, accurate and automated (see later). This study was the first such paper and
demonstrated that single breath-hold ShMOLLI T1 mapping can quantify ECV by EQ-CMR
across the spectrum of interstitial expansion, and that it is clinically more straightforward
with improvements in reproducibility and histological correlation when compared to the
older multibreath-hold FLASH techniques.
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10. RESULTS: NATIVE MYOCARDIAL T1 MAPPING IN TRANSTHYRETIN
AMYLOIDOSIS
This chapter is based on the publication below:
Fontana M, Banypersad,SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S,
Piechnik SK, Robson MD , Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD,
Whelan CJ, Gillmore JD, Hawkins PN, Moon JC. Native myocardial T1 mapping in transthyretin
amyloidosis. JACC Cardiovasc Imaging. 2014 Jan 2.
My contribution was recruiting, consenting and performing the scans of all the ATTR patients and
50 % of AL patients. I have analysed all the data as first operator, done the statistical analysis and
wrote the paper.
10.1 INTRODUCTION
Cardiac ATTR amyloidosis is a progressive and often fatal disorder that may be greatly
under diagnosed and is certainly an underappreciated cause of heart failure in the elderly
and specific ethnic populations. ATTR amyloid deposits are present in 8-16% of hearts at
autopsy in the over 80 year olds.(131) One particular TTR variant, V122I, which confers
susceptibility to amyloid cardiomyopathy has a population prevalence of 3-4% in Afro-
Caribbeans(132) and a 10% frequency among individuals of this ethnicity who present
with heart failure.(133)
Diagnosing cardiac ATTR amyloidosis is often challenging. A suggestive constellation of
ECG, echocardiography and biomarker findings are found mainly in advanced disease, but
interpretation may be confounded by common comorbidities such as left ventricular
hypertrophy, diabetes, diastolic dysfunction and renal disease.(134-136) The challenging
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diagnosis and lack of validated quantitative investigations to monitor the course of the
disease pose unique problems at a time when new specific therapies for ATTR
amyloidosis are emerging.(137)
New imaging modalities are however showing promise. Technetium-labelled bone
scintigraphy tracers, notably 3,3-diphosphono-1,2-propanodicarboxylicacid (DPD), localise
strikingly to hearts infiltrated by ATTR amyloid(47) whilst CMR LGE produces a
characteristic appearance.(138) However, neither is truly quantitative and both have
limitations.(139)
Recently, native myocardial T1 mapping has been shown in cardiac AL amyloid to track
disease.(140) Here, we assess this test in patients with ATTR amyloidosis.
10.2 HYPOTHESIS
We hypothesised that the native myocardial T1 would be elevated in this disease, that
elevation would correlate with other disease markers (e.g. intensity of DPD uptake), and
that T1 elevation would be an early marker of disease.
10.3 MATERIALS AND METHODS
AMYLOIDOSIS PATIENTS
A total of 172 individuals were categorized into 3 groups:
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ATTR AMYLOID PATIENTS
Eighty-five consecutive, consenting patients with cardiac ATTR amyloidosis (70 male; age
73±10) were recruited. The presence of cardiac amyloid was defined by presence of ATTR
amyloid in a myocardial biopsy or positive DPD scintigraphy. Eighty two percent (n=70)
had histological proof of ATTR amyloidosis by Congo red and immunohistochemical
staining of myocardial (n=30, 35%) or other tissues (n=40, 47%). All patients underwent
sequencing of exons 2, 3, and 4 of the TTR gene. Before having their CMR scans ATTR
patients were sub grouped into their pre-test probability of having cardiac involvement (no,
possible and definite cardiac involvement) as described in chapter 7.
TTR GENE CARRIERS
8 TTR gene carriers (n=8; 3 male; age 47±6) defined as individuals with pathogenic TTR
gene mutation but no evidence of disease (no cardiac uptake on 99mTc-DPD scintigraphy
and normal echocardiography, CMR, NT-proBNP and Troponin T). This group constituted
the non-cardiac involvement group.
AL AMYLOID PATIENTS
79 patients with biopsy proven systemic AL amyloid (55 male; age 62±10), the biopsies
being from the myocardium (n=6, 8%) or other tissues (n=73, 92%). Before having their
CMR scans AL patients were sub grouped into their pre-test probability of having cardiac
involvement (no, possible and definite cardiac involvement) as described in chapter 7.
These were compared with 46 patients with hypertrophic cardiomyopathy (HCM) and 52
healthy volunteers:
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HYPERTROPHIC CARDIOMYOPATHY (HCM) PATIENTS
46 patients with HCM (n=46; age 50±13, 34 male) fulfilling diagnostic criteria.(141)
Seventy-two percent of patients had an asymmetrical septal hypertrophy pattern, with the
remainder apical predominant hypertrophy. Sixty percent of patients had LV outflow tract
obstruction. Seventy-six percent of patients were found to have LGE in a variety of
locations, such as at the right ventricular insertion points or the left ventricular apex.
HEALTHY VOLUNTEERS
52 healthy volunteers (n=52, age 46±15, 17 male) were recruited as described in the
methods.
All patients and healthy controls underwent 12-lead ECG. Cardiac amyloid
patients/carriers additionally underwent assays of cardiac biomarkers (N-terminal pro-brain
natriuretic peptide [NT-proBNP] and Troponin T), echocardiography, a 6-minute walk test
where health and patient choice permitted (e.g. arthritis, postural hypotension,
neuropathy).The ATTR group also underwent DPD scintigraphy. See chapter 7 for more
details on the methods. The baseline characteristics of all patients are provided in Table 2.
All ethics were approved by the UCL/UCLH Joint Committees on the Ethics of Human
Research Committee.
EXCLUSION CRITERIA
All patients with contraindications to CMR: glomerular filtration rate <30 mL/min,
incompatible devices.
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Table 2. Baseline characteristics of patients and healthy controls.
AL, light-chain amyloidosis; ATTR, transthyretin amyloidosis; TTR transthyretin protein; eGFR,
estimated glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; AF, atrial
fibrillation; CMR, cardiovascular magnetic resonance; EDVi, end diastolic volume indexed; ESVi
end systolic volume indexed; LVEF, left ventricular ejection fraction; SVi, stroke volume indexed;
LV, left ventricular; LAAi left atrial area indexed.
CMR PROTOCOL
All subjects underwent standard CMR - see methods, including volumes, LGE and T1
mapping with ShMOLLI. For native T1 mapping, a basal and mid ventricular short-axis and
a 4-chamber long-axis were acquired using the shortened modified look-locker inversion
recovery (ShMOLLI) sequence after regional shimming (Figure 14).
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Figure 14 Examples of ROIs in ShMOLLI.
(A) pre-contrast 4 chamber and (B) pre-contrast short axis ShMOLLI image with ROIs drawn in the
basal septum of LV for native myocardial T1.
99MTC-DPD SCINTIGRAPHY
Patients were scanned using two General Electric (GE) Medical Systems hybrid SPECT-
CT gamma cameras (see chapter 7 for more details). Cardiac retention of 99mTc-DPD
was visually scored (see chapter 7 for details)
CMR IMAGE ANALYSIS
For T1 measurements, the basal ventricular short-axis or the 4-chamber ShMOLLI image
were manually contoured approximately 2 pixels in (to minimize partial volume effects)
from the endocardium and epicardium, and the average T1 value was calculated, figure
14. This was drawn without review of the LGE images. The LGE images were visually
analyzed for the presence or absence of enhancement blinded to T1 mapping results. The
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presence of LGE was classified as: circumferential in the subendocardium; diffuse
circumferential (extend into the epicardial layer); and abnormal contrast handling on T1
scout with no discernible LGE.
STATISTICAL ANALYSIS
See methods.
10.4 RESULTS
Eighty-five patients with ATTR amyloid, 8 TTR mutation carriers and 79 patients with AL
amyloid were enrolled. These were compared with 52 healthy volunteers and 46 patients
with HCM. Baseline characteristics are shown in Table 2. Amyloid patients had the
following co-morbidities: treated hypertension (22% ATTR, 15% AL); diabetes (12% ATTR,
3% AL); angiographically confirmed coronary artery disease (13% ATTR, 9%). The
echocardiogram was performed within one day of the CMR. The time gap between the
DPD and CMR was 26±36 days. Thirty-five ATTR amyloid patients were familial (V122I [n
= 18], T60A [n = 6], V30M [n = 2], E54G [n = 2], and all others unique: D38Y,G47V, E89K,
I84S,I107F, L12P,S77Y); 50 had SSA. Of the 8 gene carriers, 5 had TTR V30M and 3
T60A. Compared to definite cardiac AL patients, definite ATTR amyloid patients had a
higher LV mass indexed (133±27 vs 101±25) reduced EF (53±15 vs 61±11). The PR
interval and QRS were longer in ATTR (PR 209±54ms vs 185±38ms, QRS 116±28ms vs
106±23ms, both p<0.05). NT-proBNP and Troponin T were similar.
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T1 ELEVATION
ATTR T1 was elevated compared to HCM and normals (1097±43ms vs 1026±64ms vs
967±34ms, both p<0.0001), but was not as high as AL (AL 1130±68ms, p=0.01), and was
not elevated in mutation carriers (n=952±35ms), figure 15 and 16.
Figure 15. Characteristic examples from CMR scans.
CMR end-diastolic cine still (upper panel); ShMOLLI native T1 map (middle) and late gadolinium
enhancement (LGE) images (lower) in (left to right) healthy volunteer, HCM, definite AL and
definite ATTR patients.
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Figure 16. Native T1 in healthy volunteers, mutation carriers, HCM, definite AL and definite
ATTR.
Mean native myocardial T1±2 standard error (SE) in healthy controls subjects, gene carriers,
patients with definite AL cardiac amyloid and patients with definite ATTR cardiac amyloidosis.
T1 DIAGNOSTIC ACCURACY
ROC curve analysis was performed for the discrimination of possible or definite cardiac
amyloid from the meaningful combined differentials of HCM, systemic amyloid without
detected cardiac involvement or ATTR mutation positive patients without evidence of
cardiac amyloid. Using ROC analysis, ATTR and AL amyloid patients with possible or
definite cardiac involvement had an area under the ROC curve of 0.85(95%CI 0.79-0.92).
Example cut-off values to diagnose cardiac amyloid (high specificity) are 1048ms,
1065ms, 1090ms. These have 80%, 85%, 90% specificity and 83%, 74%, 56% sensitivity
respectively. Example cut-off values to rule out cardiac amyloid (high sensitivity) are
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954ms, 968ms, 1012ms. These have 99%, 98%, 95% sensitivity and 17%, 30%, 58%
specificity respectively. Native T1 was similarly accurate for AL and ATTR (AUC 0.84
95%CI 0.76-0.91, AUC 0.85 95%CI 0.77-0.92 respectively), figure 17.
Figure 17. ROC curve for native T1.
Receiver operating characteristic (ROC) curve for the discrimination of possible or definite cardiac
amyloid by native myocardial T1 from the clinically significant differentials of HCM; systemic
amyloid without detected cardiac involvement or ATTR mutation positive patients without apparent
cardiac amyloid for: a) cardiac amyloid, type unspecified (AL and ATTR); b) AL amyloid alone; c)
ATTR amyloid alone.AUC= area under the curve.
T1 AND DPD/LGE FINDINGS
T1 increased with increasing cardiac amyloid burden as assessed by bone scintigraphy,
(p<0.0001 for trend), figure 18. T1 was not elevated in mutation carriers (n=952±35ms) but
was in the 9 patients with isolated DPD grade 1 (1037±60ms, p=0.001), all of which had
no amyloid-like LGE (but one had inferior myocardial infarction, one had RV LGE).
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Figure 18. Native T1 and DPD grade.
Mean native myocardial T1±2 standard error (SE) in gene carriers and ATTR patients according to
different degrees of uptake on the 99TcDPD scintigraphy.
T1 AND CARDIAC FUNCTION, BLOOD BIOMARKERS, ECG AND 6 MWT
Correlations were broadly similar for AL and ATTR disease (Table 3). T1 correlated with
indices of systolic and diastolic function, indexed LV mass and known prognostic
biomarkers both in ATTR and AL amyloid patients. In ATTR patients, T1 correlated with
indexed left atrial area, 6 min walking test performance and PR and QRS duration on
ECG, whereas in AL patients, T1 correlated with indexed stroke volume, ECG limb lead
mean voltage and E deceleration time, table 3.
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Table 3. Correlations between T1 and cardiac function, biomarkers, ECG and 6 MWT in
ATTR and AL patients.
R = Pearson correlation coefficient; AL, light-chain amyloidosis; ATTR, transthyretin amyloidosis;
NT-proBNP, N-terminal pro-brain natriuretic peptide; CMR, cardiovascular magnetic resonance;
EDVi, end diastolic volume indexed; ESVi end systolic volume indexed; LVEF, left ventricular
ejection fraction; SVi, stroke volume indexed; LV, left ventricular; LAAi left atrial area indexed. * P<
0.01 level; †P<0.05.
10.5 DISCUSSION
In this, the largest ever (at that time – my later studies are larger) CMR study in patients
with amyloidosis, we found that native myocardial T1 mapping has a high diagnostic
accuracy for cardiac amyloid for both AL and ATTR when compared against HCM, a
relevant clinical differential diagnosis. Furthermore, T1 tracks cardiac amyloid burden in
both diseases, and is more sensitive for detecting early disease in gene mutation carriers
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than LGE imaging. In both amyloid types, T1 tracks markers of systolic and diastolic
function, mass and prognostic markers. In ATTR amyloid, T1 additionally correlates with
ECG PR and QRS duration and indexed left atrial area whereas in AL type, it correlates
with reductions in limb lead voltages. T1 also has functional associations with a reduction
in 6 minute walk test in ATTR amyloidosis. Interestingly and perhaps unexpectedly,(143)
T1 elevation was lower in ATTR compared to AL type.
Amyloidosis is considered the exemplar of an interstitial disease, the quantity of amyloid in
the extracellular space amounting to kilograms overall in some patients and able to
constitute the majority of the heart by weight at times.(144)
Our earlier work in AL amyloidosis demonstrated that measurement of myocardial T1
times using ShMOLLI had high diagnostic accuracy (against aortic stenosis) and tracks
disease burden.(140) Here, this work is extended to ATTR –and the diagnostic accuracy
was tested against hypertrophic cardiomyopathy, a relevant clinical differential. Although
T1 was raised in ATTR amyloid, it was not as high as in AL type, a surprising finding given
that ventricular wall thickness is greater in ATTR amyloid.(143) T1 mapping measures a
composite tissue signal from both cells and the interstitium. The extent and/or distribution
of amyloid, plus how it interacts with water or changes in the myocyte signal, could all be
implicated in causing the T1 difference. Native myocardial T1 measures a composite
signal from both the intracellular and extracellular space. Therefore the less raised T1
value found in patients with ATTR amyloidosis could be due to (amongst others), a lower
amyloid burden, less hydration of the amyloid, less collagen associated with amyloid or
differential effects on the intracellular signal. Finally AL may have additional processes
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occurring, such as oedema from possible light chain toxicity. (9) (145) Further work is
needed. Many differences in the biology of ATTR and AL cardiac amyloidosis have been
described but are not understood. This study shows specific differences between AL and
ATTR in their correlations with other parameters, for example the positive correlations in
ATTR amyloid of T1 with left atrial area, PR and QRS duration and negative correlations in
AL type of T1 with mean QRS voltage in the limb leads. These findings support the
concept of ATTR amyloid being a more purely infiltrative disease but AL having a dual
pathology with contributions from interstitial expansion and cell death.
Native myocardial T1 yielded high diagnostic accuracy in ATTR and AL amyloidosis
against the common clinical differential diagnosis of HCM. These findings combine a
number of key advantages of the mapping technique namely, the absence of need for
contrast, a single breath-hold per T1 map, simple analysis and the potential for
measurement of whole heart T1.Other investigators have proposed bone scintigraphy
using the DPD tracer as the non invasive “gold standard” for diagnosis of cardiac ATTR
amyloid.(146) However, this is semi-quantitative and is scored in 4 grades based on visual
estimation; although the radiation dose is low, serial follow-up is problematic for gene
mutation carriers. Native T1 showed high concordance with DPD scintigraphy and T1 was
measured on a continuous scale, a possible advantage. DPD scanning dichotomises
mutation carriers into DPD negative or DPD grade 1. T1 was exactly concordant with this
dichotomy, with T1 elevation and DPD grade 1 patients having no other abnormalities (no
hypertrophy, no biomarker elevation, no amyloid related LGE), suggesting both methods
identify the earliest disease expression. These preliminary findings require further
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confirmation in larger, particularly multicentre, studies with assessment of diagnostic and
prognostic performance. In native T1 measurement, there is the potential for age and
gender biases. Some of these biases may be about partial voluming and may have
reducing relevance in hypertrophied hearts. The disease biology means that the ATTR
and AL populations have a different age of presentation, with ATTR older and more male.
The HCM patients and the controls are younger. Data on age dependant changes in T1
are conflicting. A subtle trend in increasing T1 measurement has been detected in the
MESA study (r2=0.021, 5ms/decade in men but not women)(147), but a reduction in T1
with age in women but not men with ShMOLLI(148). Fortunately, most of the effect sizes
detected here are large compared to the potential biases, and some of them go in the
opposite direction to a confounding bias: for example, the (10 years younger) ALs have
more T1 elevation than the ATTR patients by 33ms – the opposite way to the age related
bias that most experts expect to exist. The ATTRs are 82% male whereas AL is 72% male.
A male:female difference in T1 is not found in the over 45s in the Piechnik paper(148), but
even if the 24ms difference found in the young males vs females was present, this would
make only a ~3ms overall difference, ~10% of the difference found in this paper.
Furthermore, ATTR had more hypertension, coronary artery disease and diabetes. All
these might be expected to contribute to increase in T1 times in ATTR – the opposite trend
to that found, but potentially leading to a possible underestimation of the difference
between AL and ATTR patients.
The main limitation of this study is the lack of histological validation of the technique. This
is challenging because diagnosis in many patients was secured following biopsy of non-
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cardiac sites, and it was not ethical to obtain cardiac biopsies for research given its
invasive nature. Furthermore, quantification of amyloid (rather than presence/absence) is
challenging in myocardial biopsies due to its often patchy and microscopic distribution. The
second limitation is lack of biopsy evidence of amyloid in 18% of ATTR patients. However
this cohort of patients was fully characterized with all the other clinical investigative
techniques currently available. When combined, these are known to provide high
diagnostic accuracy. CMR extracellular volume measurement was not included in this
study. No follow-up data are available at this time. T1 mapping is yet to be standardized
across manufacturers, although efforts are underway to do this. In our paper we analysed
only a single region of interest in the septum. A segmental or whole heart approach should
be explored in the future.
In conclusion, native myocardial T1 mapping detects cardiac ATTR amyloid and has
similar performance for diagnosis and tracking disease in both ATTR and AL amyloidosis.
The lower T1 elevation in ATTR amyloid, and the specific differences between AL and
ATTR correlations with other cardiac findings, may support a concept of ATTR amyloid
being a more purely infiltrative disease but AL type having a dual pathology with both
interstitial expansion and cell death.
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11. RESULTS: MYOCYTE RESPONSE IN AL AND ATTR CARDIAC
AMYLOIDOSIS
With the work described in this chapter I won the Early Career Award at SCMR 2014.
This chapter is based on paper below.
Fontana M, Banypersad SM, Tribel TA, Maestrini V, Abdel-Gadir Amna, Lane T, Gilbertson JA,
Hutt DF, Lachmann HJ, Whelan CJ, Wechalekar AD, Herrey AS, Gillmore JD, Hawkins PN, Moon
JC. Cardiac ATTR and AL amyloid deposits evoke differential myocyte responses: new
pathophysiological insights from Cardiovascular Magnetic Resonance. Radiology. 2015 May
21:141744.
My contribution was recruiting, consenting and performing the scans of all the ATTR patients and
60% of AL patients. I have analysed all the data as first operator, done the statistical analysis and
wrote the paper.
11.1 INTRODUCTION
The extent or severity of cardiac involvement in amyloidosis can be described by
ventricular wall thickness, LV mass and the degree of transmurality of LGE on CMR
(4,135,149-151). By these measures, ATTR is morphologically more severe than AL.
Other measures, such as diastolic impairment, brain natriuretic peptide and troponin are
higher in AL than ATTR (152), and, crucially, the prognosis is much worse in AL. This
discordance is not understood (4,135) but has been ascribed to either a direct toxic effect
of the amyloid in AL (153) or a faster rate of amyloid deposition in AL than ATTR leading to
differences in the resulting myocardial damage. However, in vivo tools to assess the
differences in the degree of amyloid deposition or myocyte response in ATTR and AL
cardiac amyloid have not previously existed, leaving a knowledge gap of disease
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pathophysiology that needs to be addressed to ensure optimal early phase clinical testing
of the heterogeneous new amyloid therapies now in development (154).
CMR can now measure: 1- Native T1 signal, a composite signal from the interstitium and
the cell, sensitive to extracellular amyloid (140), fibrosis (155), and particularly sensitive to
myocardial edema, in which elevations may be very high (156); 2- ECV and Intracellular
Volume fractions (ICV) (representing the fraction of myocardium, which is amyloid and
cells, respectively (144)); 3- Total Amyloid Volume and Total Cell Volume, calculated by
multiplying the ECV and ICV by the myocardial volume from cine images. (121,144).
11.2 HYPOTHESIS
We report here studies of these new in vivo CMR tools enabling amyloid and myocytes to
be characterized and quantified separately, which elucidate substantial differences in the
pathogenesis of AL and ATTR amyloidosis.
11.3 MATERIAL AND METHODS
AMYLOIDOSIS PATIENTS
A total of 210 patients were categorized into 3 groups:
AL AMYLOIDOSIS PATIENTS
92 patients with biopsy proven systemic AL amyloid (60 male; age 62±10), with biopsies
from the myocardium (n=7, 8%) or other tissues (n=85, 92%). These 92 patients include
50 patients studied previously in an AL only study (144). Before having their CMR scans
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ATTR patients were sub grouped into their pre-test probability of having cardiac
involvement (no, possible and definite cardiac involvement) as described in chapter 7.
ATTR AMYLOIDOSIS PATIENTS
110 consecutive, consenting patients with cardiac ATTR amyloidosis (94 male; age
71±11) were recruited. The presence of cardiac amyloid was defined by presence of ATTR
amyloid in a myocardial biopsy or positive technetium-labelled bone scintigraphy tracers,
notably 3,3-diphosphono-1,2-propanodicarboxylicacid (DPD scintigraphy). Seventy
percent (n=77) had histological proof of ATTR amyloidosis by Congo red and
immunohistochemical staining of myocardial (n=32, 29%) or other tissues (n=45, 41%). All
patients underwent sequencing of exons 2, 3, and 4 of the TTR gene. Before having their
CMR scans AL patients were sub grouped into their pre-test probability of having cardiac
involvement (no, possible and definite cardiac involvement) as described in chapter 7.
TTR GENE CARRIERS
8 TTR gene carriers (n=8; 3 male; age 47±6) defined as individuals with pathogenic TTR
gene mutation but no evidence of disease (no cardiac uptake on DPD scintigraphy and
normal echocardiography, CMR, N-terminal pro-brain natriuretic peptide [NT-proBNP] and
Troponin T). This group constituted the non-cardiac involvement group.
HEALTHY VOLUNTEERS
47 healthy volunteers (n=47, age 45±15, 21 male) were recruited (see chapter 7 for more
details). All patients and healthy controls underwent 12-lead ECG. Cardiac amyloid
patients/carriers additionally underwent assays of cardiac biomarkers (NT-proBNP and
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Troponin T), echocardiography, 6-minute walk test where health and patient choice
permitted (e.g. arthritis, postural hypotension, neuropathy). The ATTR group also
underwent DPD scintigraphy. The baseline characteristics of all patients are provided in
Table 4.
Table 4. Baseline characteristics of patients and healthy controls.
AL, light-chain amyloidosis; ATTR, transthyretin amyloidosis; TTR transthyretin protein; eGFR,
estimated glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; AF, atrial
fibrillation; CMR, cardiovascular magnetic resonance; EDVi, end diastolic volume indexed; ESVi
end systolic volume indexed; LVEF, left ventricular ejection fraction; SVi, stroke volume indexed;
LV, left ventricular; LAAi left atrial area indexed. * P< 0.01 level; †P<0.05.
EXCLUSION CRITERIA
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All patients with contraindications to CMR: glomerular filtration rate <30 mL/min,
incompatible devices.
CMR PROTOCOL
CMR included EQ-CMR with standard LGE (+/- PSIR) and T1 mapping using ShMOLLI.
Regions of interest drawn without reference to the LGE images (157) (Figure 19). See
chapter 7 for more details on the methods.
Figure 19. Examples of ROIs in ShMOLLI.
4-chamber ShMOLLI (A) pre-contrast and (B) post-contrast with ROIs drawn in the basal septum.
CMR IMAGE ANALYSIS
A single ROI was drawn directly in the septum in each 4 chamber T1 map performed prior
to contrast administration and at equilibrium (Figure 19). A haematocrit was taken in all
subjects on the same day. Five different parameters were calculated (114):
1- Native myocardial T1
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2- ECV = (1 - haematocrit) x (ΔR1myocardium / ΔR1 blood)
3- ICV= 1 - ECV
4- Total Amyloid Volume = ECV x LVmassi
5- Total Cell Volume = ICV x LVmassi
STATISTICAL ANALYSIS
See methods (chapter 7).
11.4 RESULTS
The baseline characteristics of the 92 AL and 110 ATTR patients are shown in Table 4.
Forty-four ATTR amyloidosis patients were familial (V122I [n = 22], T60A [n = 9], V30M [n
= 3], E54G [n = 2], S77Y [n = 2] and all others unique: D38Y, G47V, E89K, I84S, I107F,
L12P); 66 had senile systemic amyloidosis (SSA). Of the eight gene carriers, five had TTR
V30M and 3 T60A. As expected, for the definite cardiac involvement AL and ATTR
subsets, there were differences in cardiac function and morphology, table 4, with AL
showing a lower LV mass indexed (107±30 g/m2 vs 134±28 g/m2, p<0.0001) and higher
EF (62%±11% vs 53%±14%, p<0.0001). Differences in the ECG were present: the PR
interval and QRS were shorter in AL (PR 189±43 ms vs 215±56 ms, QRS 106±24 ms vs
117±28 ms, both p<0.05). NT-proBNP and Troponin T biomarker concentrations were
similar.
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NATIVE T1, ECV, TOTAL AMYLOID VOLUME AND TOTAL CELL VOLUME IN AL AND ATTR
ECV and T1 were elevated in all types of amyloidosis compared to healthy volunteers
(ECV: AL 0.54±0.07, ATTR 0.58±0.06 vs 0.27±0.03, both p<0.0001, T1: AL 1126±70ms,
ATTR 1101±46ms vs 968±36ms, both p<0.0001) (Figure 20 and 21).
Figure 20. Characteristic example CMRs in AL, ATTR patients and healthy volunteer.
Characteristic examples from CMR scans in (upper, mid, lower panels) definite AL, definite ATTR
patient and healthy volunteer. CMR end-diastolic cine still (left panel); ShMOLLI native T1 map
(center left); late gadolinium enhancement (LGE) (middle right) and ShMOLLI T1 map at
equilibrium.
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Figure 21. Native T1 and ECV in healthy volunteers, definite AL and definite ATTR.
Native T1 is higher in AL than ATTR – whereas ECV is higher in ATTR than AL. This discordance
suggests an additional process is causing native T1 elevation in AL – potentially edema.
The extent of the elevation was discordant between AL and TTR: the ECV and Total
Amyloid Volume were higher in ATTR (ECV 0.58±0.06 vs 0.54±0.07, p=0.001; Total
Amyloid Volume 74±19ml/m2 vs 54±15ml/m2, p<0.0001), whereas native T1 was higher in
AL (1126±70ms vs 1101±46ms, p<0.05) (Figure 21 and 22). ATTR had a higher Total Cell
Volume than normal subjects (53±12ml/m2 vs 45±11ml/m2, p=0.001), but the Total Cell
Volume in AL was unchanged (47±17ml/m2 vs 45±11ml/m2, p=1) (Figure 22).
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Figure 22. LV mass indexed, ECV, Total Amyloid Volume, Total Cell Volume in healthy
volunteers, definite AL and definite ATTR.
LV mass indexed (left upper panel), ECV (right upper panel), Total Amyloid Volume (left lower
panel), Total Cell Volume (right lower panel) in healthy controls subjects, definite AL cardiac
amyloidosis and patients with definite ATTR cardiac amyloidosis.
ECV AND TOTAL CELL VOLUME ACCORDING TO THE DEGREE OF CARDIAC INVOLVEMENT
When AL and ATTR patients were divided according to the degree of cardiac involvement
in three categories (no, possible and definite cardiac involvement) ECV increased between
groups in both AL and ATTR (AL: 0.30±0.6 vs 0.40±0.07 vs 0.54±0.07, for all p<0.0001
ATTR: 0.27±0.03 vs 0.36±0.08 vs 0.58±0.06, for all p<0.001), (Figure 23).
94
The Total Cell Volume was discordant in AL and ATTR, as the total cell volume did not
increase between groups in AL patients but increased in ATTR patients (AL: 47±14 vs
45±14 vs 47±17, p=1 for all; ATTR: 42±9 vs 44±10 vs 53±12, no cardiac involvement vs
definite p<0.05, possible vs definite cardiac involvement p<0.05, other comparisons not
significant), (Figure 23).
Figure 23. ECV and Total Cell Volume in AL and ATTR patients divided according to the
degree of cardiac involvement.
ECV in AL (left upper panel), Total Cell Volume in AL (right upper panel), ECV in ATTR (left lower
panel), Total Cell Volume in ATTR (right lower panel). * P< 0.01 level; †P<0.05.
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T1 AND ECV AND CARDIAC FUNCTION, BIOMARKERS, ECG AND 6 MWT
Correlations were similar for T1 and ECV in AL and ATTR patients (Table 5). They
correlated with indices of systolic and diastolic function, indexed LV mass and known
prognostic biomarkers. All the correlations were stronger with ECV than native T1.
Table 5. Correlations between native T1 and ECV with cardiac function, biomarkers, ECG
and 6 MWT.
R = Pearson correlation coefficient; AL, light-chain amyloidosis; ATTR, transthyretin amyloidosis;
NT-proBNP, N-terminal pro-brain natriuretic peptide; CMR, cardiovascular magnetic resonance;
EDVi, end diastolic volume indexed; ESVi end systolic volume indexed; LVEF, left ventricular
ejection fraction; SVi, stroke volume indexed; LV, left ventricular; LAAi left atrial area indexed. * P<
0.01 level; †P<0.05.
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11.5 DISCUSSION
AL and ATTR amyloidosis have a different natural history and prognosis, but in both,
cardiac involvement is the main driver of prognosis. Amyloidosis is used as the exemplar
of an interstitial disease - whilst the quantity of amyloid expanding the body’s extracellular
space varies substantially, it can exceed kilograms in some patients. We report here a
comparison of AL and ATTR amyloidosis combined measurements of amyloid burden (the
ECV and Total Amyloid Volume, estimates respectively of the amyloid fraction and amyloid
volume) but also the ICV (a measure of the myocyte volume fraction), along with native T1
signal, a composite from both myocytes and interstitium, which is mainly driven by the
amount of water in the tissue. Both ECV and Total Amyloid Volume, i.e. the amyloid
burden, are very elevated in ATTR amyloidosis and to a significantly greater degree than
in AL patients. The greater amyloid burden in ATTR patients is also associated with an
increased myocyte volume suggesting a compensatory myocyte hypertrophy response in
this type of amyloidosis, which may favorably influence clinical outcome. However, in AL
amyloidosis there no net differences in myocardial cell volume compared with healthy
volunteers, suggesting AL in general either has no myocyte hypertrophy or any such
hypertrophy is balanced by myocyte loss. Intriguingly and importantly, the greater
elevation in T1 signal in AL patients compared with ATTR in the presence of a smaller
amyloid burden points to an additional process, the most likely explanation being
myocardial edema (158). This hypothesis is plausible and compatible with hypertrophy
balanced by myocyte loss – a scenario that would fits with more myocardial damage in AL
as evidenced by greater troponin release than occurs in ATTR type, although debate
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continues as to whether this may result from light chain/AL fibril toxicity or differing rates of
amyloid deposition (4,153). If amyloidosis is considered solely as an infiltrative myocardial
disease, the higher ECV in ATTR compared to AL is paradoxical as ATTR has a more
benign prognosis (4). A protective hypertrophic response in ATTR may be part of the
explanation. When a third parameter, native T1 is added, this paradoxical difference can
be explained by edema in AL and a further refinement of a model comes into view with, in
AL, a hypertrophic response balanced by myocyte loss and associated edema. The results
also add nuance to the debate of nomenclature for the wall thickening found in amyloid:
the findings suggest that “hypertrophy” is appropriate for ATTR, whereas in AL the
situation remains more complex.
These results and methodologies deepen our understanding of cardiac amyloid by firstly
quantifying amyloid deposition, but secondly providing insights into myocyte response
which is different in ATTR and AL. Further work is needed to explore these models - and
they generate testable hypotheses: for example, the above model suggests in AL that very
high T1 might be associated with a) troponin release and b) T2, the traditional myocardial
parameter used to image edema. Furthermore, if light chains are “switched off” using
chemotherapy, T1 may be expected to fall faster than ECV changes and track troponin
and BNP reduction. Other explanations are, however, possible. The ECV is fundamentally
tracking extracellular water. Collagen deposition or the hydration of collagen, possibly
reflecting maturity of amyloid, may be different between AL and ATTR. The T1 is
measuring both extracellular and intracellular signal so either AL myocytes or amyloid
could have higher native T1 or ATTR amyloid and myocytes could have lower native T1.
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Other as yet unknown factors in addition to collagen, amyloid and edema could change
this – known examples are iron or fat infiltration, although neither is likely in amyloid.
Despite these limitations, overall, these findings support the concept that cardiac amyloid
is not a disease of solely infiltration but of compensated infiltration and with superimposed
toxicity and eventual failure of compensation - which is measurably more prominent in AL
compared to ATTR (153,159). This different mechanism of myocardial damage and
different myocardial response could have important implications in terms of future
therapeutic targets. Furthermore the ability of measuring treatment response not only in
terms of neurohormonal activation, but also in terms of structural changes is important in
the process of drug development. More specifically, with T1 mapping by cardiac CMR we
will be able to measure the effect of treatment at 3 different levels, i.e. infiltration (amyloid
burden, ECV), edema (native T1) and myocyte response (intracellular volume), providing a
richer understanding of the pathophysiological mechanism.
Although this series represents the largest prospective CMR study of the AL and ATTR
amyloid (until my later studies – see next chapter) with the use of innovative techniques
further work is needed. A limitation of this study is the lack of histological validation. There
was no biopsy evidence of amyloid in 30% of ATTR patients – but this cohort of patients
was fully characterized with all other clinical investigative techniques currently available
including DPD scanning. This composite diagnostic pathway is known to provide high
diagnostic accuracy. No follow-up was imaging was performed and therefore change over
time was not tracked. Despite this, these results set the scene for a more sophisticated
approach to cardiac amyloidosis, refocusing on the myocyte.
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12. RESULTS: PROGNOSTIC VALUE OF LATE GADOLINIUM
ENHANCEMENT CARDIOVASCULAR MAGNETIC RESONANCE IN
CARDIAC AMYLOIDOSIS
With the work described in this chapter I was shortlisted for the Early Career Award (clinical
translational) at SCMR 2015 and for the Melvin Judkins Young Investigator Award 2014.
This chapter is based on the publication below.
Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W,
Rosmini S, Bulluck H, Sayed RH, Patel K, Mahmood S, Bucciarelli-Ducci C, Whelan CJ, Herrey
AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins
PN, Moon JC. Circulation. 2015 Sep 11. pii:
My contribution was recruiting, consenting and performing the scans of all the ATTR patients and
70% of AL. I have analysed all the data as first operator, done the statistical analysis and wrote the
paper.
12.1 INTRODUCTION
The prognosis of immunoglobulin AL and ATTR amyloidosis is substantially influenced by
the presence and severity of cardiac involvement which then governs therapeutic
strategies.(4,160) Although blood biomarkers are useful guides for risk stratification,(7)
they are not specific for cardiac involvement, and current strategies do not ascertain all
patients at risk. Mortality, despite treatment progress, remains high.(9,35,161,162) Over
the last decade, new chemotherapy regimens and stem cell transplantation have been
associated with improved survival in patients with AL amyloidosis, but the prognosis
remains poor in those with cardiac involvement, which also contributes substantially to
treatment related morbidity and mortality. There remains much unmet need for improved
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non-invasive criteria to stratify risk in selecting optimal therapy whilst avoiding serious
toxicities.
Cardiac amyloid deposition represents a key process in amyloid pathophysiology.(45,163)
CMR with LGE identifies myocardial infiltration: after the administration of contrast, CMR
shows a characteristic pattern of global subendocardial LGE coupled with abnormal
myocardial and blood-pool gadolinium kinetics.(138,164) However, despite excellent
diagnostic accuracy for the presence of amyloid, conflicting results have been reported
regarding the prognostic impact AL amyloidosis, and no studies have been published in
ATTR amyloidosis.(149,165-171) Newer techniques, particularly phase sensitive inversion
recovery, an LGE image reconstruction technique that is less sensitive to operator choice
of null point and renders signal intensity truly T1 weighted, may better reflect extent of
cardiac involvement(172) and thereby improve risk stratification.
We report here a prospective CMR study conducted in amyloidosis, in which we
investigated the prognostic value of LGE in 250 consecutive CMR-eligible subjects.
The aims of the study were to assess: 1- patterns of LGE and the benefit of new more
robust approaches (PSIR); 2- correlation with the cardiac amyloid burden; 3- the
prognostic impact of LGE in both AL and ATTR cardiac amyloidosis.
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12.2 METHOD
AMYLOIDOSIS PATIENTS
A total of 250 patients were categorized into 3 groups: Outcome (dead/alive) was
ascertained using death certificates
SUBJECTS WITH AL AMYLOID
119 patients with biopsy proven systemic AL amyloid (77 male, 65%; age 62±10 years),
with biopsies from the myocardium (n=7, 6%) or other tissues (n=112, 94%).
SUBJECTS WITH ATTR AMYLOID
122 consecutive, consenting patients with ATTR amyloidosis (101 male, 83%; age
71±11years) were recruited. 69 percent (n=84) had histological proof of ATTR amyloidosis
by Congo red and immunohistochemical staining of myocardial (n=35, 29%) or other
tissues (n=49, 40%). The presence of cardiac amyloid was defined by presence of ATTR
amyloid in a myocardial biopsy or positive technetium-labelled bone scintigraphy using
3,3-diphosphono-1,2-propanodicarboxylicacid (DPD scintigraphy). All subjects underwent
sequencing of exons 2, 3, and 4 of the TTR gene.
TTR GENE MUTATION CARRIERS
In addition, there were 9 subjects with amyloidogenic TTR gene mutations (3 male, 33%;
age 47±6 years) defined as individuals with no evidence of clinical disease (no cardiac
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uptake on DPD scintigraphy and normal echocardiography, CMR, N-terminal pro-brain
natriuretic peptide [NT-proBNP] and Troponin T).
CMR IMAGE ACQUISITION
CMR was standard volumes and LGE with PSIR in 43% of patients. T1 mapping was
ShMOLLI with regions of interest drawn in the 4 chamber view at the level of the basal and
mid inferoseptum (2 segments, large region of interest).(157)
CMR LGE INTERPRETATION
During interpretation, prior to our adoption of PSIR for all amyloidosis patients, because
myocardial nulling can be difficult in the presence of amyloid, any confusion with MAG-IR
images was resolved by selecting the images that most matched the post contrast T1
maps – with “bright” LGE expected to correlate with areas with the lowest post contrast T1
(i.e. the highest gadolinium concentration, the highest interstitial expansion).
The LGE pattern was classified by 2 different observers (MF and SP) into 3 groups
according to the degree of transmurality: 1-no LGE; 2-subendocardial LGE (when there
was global subendocardial involvement but no transmural LGE); 3-transmural LGE (when
the LGE was extending transmurally), (Figure 24). Thus a patient with basal transmural
LGE but apical subendocardial LGE would be classified as “transmural LGE”.
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Figure 24. Characteristic PSIR LGE patterns in 3 AL and 3 ATTR patients.
No gadolinium enhancement (LGE) (left panels); Subendocardial LGE (middle); transmural LGE
(left panels).
CMR PSIR VERSUS MAG-IR
A sample of 100 images (50 PSIR, 50 MAG-IR reconstruction) was analyzed for
concordance or discordance with the post-contrast T1 maps which were used as the truth
standard (Figure 25). We considered that nulled tissue should be the tissue with the least
contrast (longest T1 on post contrast T1 map). This means that a normal subject should
have nulled myocardium; a high infiltration amyloid patient bright myocardium (transmural)
and nulled blood, and the possibility of intermediate blood and myocardium nulling
concurrently (typically with “bright” endocardium). This is discussed further in the figure
legends and discussion.
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Figure 25. Characteristic CMRs in 4 different patients.
LGE with magnitude reconstruction (left); LGE with PSIR (middle) and post contrast ShMOLLI T1
maps (right). On PSIR, there is 100% concordance between myocardial T1 and LGE: firstly areas
of low T1 (darkest blue) and focal areas of LGE; secondly where myocardial T1 is lower than blood
T1, global LGE is demonstrated and thirdly, where myocardial T1 is higher than blood T1, no LGE
is demonstrated. On MAG-IR images, discordance is present in all 4 of these cases: mid
myocardial rather than subendocardial (Panel A); apical rather than basal (panel B), transmural
LGE rather than normal (panel C) and normal rather than transmural (panel D).
105
. STATISTICAL ANALYSIS
See methods. In addition, survival was evaluated using Cox proportional hazards
regression analysis, providing estimated hazard ratios (HR) with 95% confidence intervals
(CI) and Kaplan Meier curves. Variables selected a priori for the clinical relevance and first
explored with univariate Cox regression were entered in the multivariable models.
Multivariable models evaluated the independent predictive value of LGE above other
clinically and statistically significant covariates. Harrell’s C statistic was calculated for the
different models.
12.3 RESULTS
STUDY POPULATION
The details of the 250 subjects are shown in table 1. At the time of scanning, the AL
amyloidosis cohort had 46 new untreated (to date) patients; 21 patients undergoing
second or third line therapy and 52 stable patients (complete or very good response 80%;
stable partial response 20%). UK first line therapy at the time of this study was typically
Cyclophosphamide, Thalidomide and Dexamethasone (CTD) or Cyclophosphamide,
Bortezomib and Dexamethasone (CVD). Relapse therapy was typically CVD or a
Lenalidomide-containing regimen. The TTR mutations were: V122I [n = 23], T60A [n = 13],
V30M [n = 10], E54G [n = 2], S77Y [n = 2], E89K [n = 2] and D38Y, G47V, E89K, I84S,
I107F and L12P in one case each. Of the 9 asymptomatic individuals with TTR mutations,
5 had TTR V30M and 3 T60A and 1 S77Y.
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Table 6. Main Clinical Characteristics, echocardiographic and ECG findings in patients with
AL and ATTR amyloidosis according to the LGE pattern.
 ∞less 10 patients with non-diagnostic MAG-IR LGE images. p-values: * p<0.05,  † p<0.01,  ‡ 
p<0.001 for trend across different pattern of LGE.
MAG-IR VERSUS PSIR
MAG-IR LGE and T1 maps were discordant in 57% (where the operator was selecting the
inversion time according to his/her best judgment) meaning that operator TI selection was
mainly incorrect. Ten patients with MAG-IR only had not one LGE images that matched
the T1 mapping for classification (implying the operator systematically kept the TI incorrect
for the whole scan). All patients with PSIR LGE had diagnostic images. PSIR LGE and T1
maps were never (0%) discordant, Figures 25 and 26. MAG-IR could be incorrect in three
ways: inappropriately nulling global LGE, Figure 25D, particularly the highest ECV cases;
to get the incorrect distribution (especially making LGE apical rather than basal, Figure
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25A and B; or creating transmural LGE where there should be global nulling (and the ECV
was low), Figure 25C. With PSIR, the longest T1 tissue after windowing is always nulled.
Figure 26. Two patients with MAG and PSIR LGE reconstruction images.
Two patients (top and bottom) with MAG and PSIR LGE reconstruction images (left). In both
patients, the MAG and PSIR are discordant with opposite LGE patterns. Only one can be correct.
The tissue to null is the one with the slowest T1 recovery (i.e. the least gadolinium). On the right
are the signal intensity curves as the TI varies for MAG and PSIR. How the operator sets the TI
matters in MAG imaging – but not in PSIR. The operator set the TI for both patients at X, nulling
the wrong tissue. Only had they set the TI greater than Y would the image have been correct. With
PSIR, the TI could have been set anywhere and the tissue with the least gadolinium has lower
signal and will be nulled after windowing.
LGE PATTERN AND CORRELATION WITH ECV
Three patterns of LGE are observed: no LGE; subendocardial LGE and transmural LGE,
Figure 24. There was good agreement in the assignment of these patterns between two
observers (ICC 0.97, 95%CI 0.97-0.98). All patterns were present in AL and ATTR cardiac
amyloidosis (Figure 27) but to different extents, with subendocardial LGE being more
prevalent in AL (39% in AL vs 24% in ATTR, p<0.05) and transmural LGE more prevalent
in ATTR (27% in AL vs 63%, p<0.0001), Figure 27.
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Figure 27. LGE patterns correlation with amyloid burden.
Histograms showing the prevalence of the different LGE patterns (upper panels) in AL and ATTR
patients; correlation with the amyloid burden (lower panels), measured as extracellular volume
(ECV) in AL and ATTR patients. Bonferroni-adjustment was applied.
Increasing LGE (none, subendocardial, transmural) was associated with increasing ECV
(AL: 0.31±0.04, 0.47±0.06, 0.58±0.07; ATTR: 0.29±0.04, 0.50±0.05, 0.60±0.05, for both
p<0.0001), Figure 27. In ATTR, this correlated also with DPD grade (p<0.0001). Apparent
transitions are evident with subendocardial LGE appearing at an ECV of 0.40-0.43 for AL
and 0.39-0.40 for ATTR and transmural at 0.48-0.55 for AL and 0.47-0.59 for ATTR.
However 39% of the no LGE patients had ECV elevation as compared to normal range
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(ECV elevation between 0.32 and 0.40). Of the patients with no LGE and increased ECV,
4 patients had mutant ATTR (DPD grade 1 in 3; grade 0 in one) and 17 patients had AL.
Increasing LGE (none, subendocardial, transmural) was associated in both AL and ATTR
with lower systolic blood pressure, ECG changes (prolonged PR interval, prolonged QRS
in ATTR), increased NT-proBNP, structural and functional changes (increased LV mass,
increased end systolic volume, decreased stroke volume, decreased ejection fraction, left
atrial dilatation), increasingly abnormal tissue characterisation (elevated native T1 and
ECV, Table 2) and more severe echo diastolic dysfunction. In ATTR, increasing LGE was
also associated with decreased functional capacity (6 minute walk test).
Table 7. CMR findings in patients with AL and ATTR amyloidosis according to the LGE
pattern.
∞less 10 patients with non-diagnostic MAG-IR LGE images. p-values: * p<0.05,  † p<0.01,  ‡ 
p<0.001 for trend (one-way analysis of variance) in AL and ATTR patients across different pattern
of LGE.
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LGE PATTERN AND PROGNOSIS
At follow up (mean 24±13 months), 67 (27%) of 250 patients had died. Transmural LGE
was a significant predictor of mortality in the overall population (HR 5.4, 95% CI: 2.1-13.7,
P<0.0001) (Figure 28).
Figure 28. Kaplan Meier curves for late gadolinium enhancement.
Kaplan Meier curves for late gadolinium enhancement patterns in all patients (upper panel), AL
(left lower panel) and ATTR patients (right lower panel).
111
The survival curves indicates that there is an approximately 92% chance of survival at 24
months in patients with a no LGE (92% in AL 94% in ATTR) compared to 81% for patients
with subendocardial LGE (81% in AL 81% in ATTR) and 61% with transmural LGE (45% in
AL 65% in ATTR). The median survival in patients with transmural LGE was 17 months in
AL and 38 months in ATTR. Transmural LGE was significantly associated with mortality
(HR = 4.1, 95% CI: 1.3-13.1, p<0.05) in multivariable Cox models that included NT-
proBNP, ejection fraction, stroke volume indexed, E/E’, left ventricular mass indexed
(Troponin results were not available in all patients). NT-ProBNP and stroke volume
indexed also remained independently predictive (Table 3). Harrel C statistics for this model
was 0.72.
The Harrel C statistics of a comparable preCMR-model including demographics, systolic
and diastolic function parameters and biomarkers (Age, EF, EE, BNP, interventricular
septal wall thickness) was 0.67.
12.4 DISCUSSION
Cardiac infiltration is the chief driver of prognosis in systemic amyloidosis, and
stratification of patients is essential for prognosis and optimal management, including
selection of patients to receive aggressive higher risk therapies and to minimise cardiac
toxicities. Echocardiography, once the gold standard cardiac investigation in amyloidosis,
has limited sensitivity and specificity, and risk stratification is currently places great
emphasis on blood biomarkers. However, these strategies do not identify all amyloidosis
patients at risk, and the findings of studies on evaluation of cardiac involvement by CMR
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have been conflicting.4-7, 19 Recently, considerable interest has emerged in using LGE to
improve the risk stratification model,(149,165-171) but studies in AL cardiac amyloidosis
have been few, mostly small, retrospective and have employed non-standardized LGE
approaches, and have produced inconsistent results(138,165,166,168,169,171). No
studies have been published in ATTR amyloidosis.
In the present study, the largest CMR study in amyloidosis to date, we showed that
misleading results using the MAG-IR LGE technique was likely to account for the
conflicting finding that have previously been published. By convention, LGE should display
containing the most contrast (i.e. shortest T1 on T1 maps). For amyloidosis, myocardium
can contain more gadolinium than blood – under those circumstances, myocardium should
appear globally bright (transmural LGE). It is a property of MAG imaging that signal is
highly dependent and non-linear with user defined choice of the TI (time to null), Figure 26,
and images can be “inverted” with the wrong TI choice. When all of the myocardium is
abnormal (frequent in cardiac amyloidosis), the abnormal myocardium could be wrongly
nulled, as the MAG-IR relies on ‘nulling’ what is perceived to be normal myocardium. This
limitation was quantified in our study by comparison with a true standard of post contrast
T1. More importantly, this problem does not occur with the PSIR approach. PSIR
substantially removes the issue of operator selected inversion time and completely
removes the potential for a “mirror image”. On a PSIR reconstruction when windowed by
the operator, the tissue with the longest T1 (least gadolinium - blood or myocardium), after
windowing, is always nulled. The practical result is this: a) if myocardium is globally nulled
by PSIR, the ECV is less than blood and <0.4-0.43: any amyloid present (detectable by an
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ECV>0.32), is not extensive. b) above this, LGE areas appear particularly in the sub
endocardium. PSIR LGE areas are the areas of most amyloid deposition in the heart; c)
above an ECV of 0.47-0.59, blood has less gadolinium than myocardium and blood is
nulled – myocardium appears uniformly bright – heterogeneity is present but it is swamped
by all the myocardium becoming bright. Examples of MAG-IR errors are in Figure 25: mid
myocardial rather than subendocardial (Figure 25 panel A); apical rather than basal
(Figure 25 panel B), transmural LGE rather than normal (Figure 25 panel C) and normal
rather than transmural (Figure 25 panel D).(172,173) Accordingly, we believe that PSIR
should be universally adopted for amyloid LGE imaging – particularly as PSIR-LGE is
easily available from all scanner manufacturers (whereas T1 mapping is not yet).
Using PSIR, three patterns were relatively easy to determine, and the previously frequently
described LGE pattern of “patchy” LGE was not evident using PSIR – many of these on
PSIR appeared to have transmural LGE. A key insight is that amyloid cardiac involvement
is not dichotomous, but a continuum from no LGE to subendocardial to transmural tracking
increasing ECV (Figure 29).(70,174) Transmural LGE appears to be the pattern that
carries the most adverse prognosis – it is an important marker of all-cause mortality, after
adjustment for other relevant disease variables and regardless of treatment status (indeed
irrespective of whether patients are presenting at diagnosis or years into the disease
process). Indeed, in ATTR, the majority of the deaths are in patients with transmural LGE
(no LGE, subendocardial LGE, transmural: 1,6,24 deaths respectively).
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Figure 29. Hypothesized cardiac amyloid progression across time.
When amyloid starts to accumulate 3 steps can be identified; 1-No evidence of LGE but increase
in native T1 and extracellular volume (ECV); 2-Further increase in T1 and ECV and appearance of
subendocardial LGE; 3-Further increase in native T1 and ECV and progression to transmural LGE.
Within this spectrum, the degree of involvement is important, and with transmural LGE
defining the high risk group. The prevalence of patients in the different stages of disease
progression (Figure 29) is different in AL and ATTR. 39% of the no LGE patients had
ECVs in the 0.32 to 0.4 range, particularly AL amyloidosis. It is expected that ATTR patient
must pass through this phase, but it is not clinically recognised. Early cardiac involvement
in AL is detected through cardiac screening of AL patients presenting with extracardiac
disease. The majority of ATTR patients (wild type ATTR and mutant ATTR associated
with the variant V122I) present with heart failure symptoms that appear only when
advanced (LGE is invariably present, mostly transmural). This has potential treatment
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implications. Currently, patients with subendocardial LGE may be classified as “cardiac
involvement” and denied therapies, which are known to improve long term survival – but
which are contraindicated in “cardiac involvement” – such as stem cell transplants (AL),
some chemotherapy regimens (AL) and liver transplants (ATTR). More data is needed
and consideration of cardiac involvement as a continuum should provide the insights into
the impact of different degrees of cardiac infiltration and possibly changing the current
therapeutic approach. Within the transmural pattern, the median survival is significantly
different in the two amyloid types, 17 months for AL and 38 months for ATTR. These
findings support the concept that cardiac amyloid is not a disease of solely infiltration but
may have with superimposed toxicity (AL > ATTR) or that the rate of accumulation is
myotoxic, a contributor to different prognosis between AL and ATTR despite ATTR higher
degrees of LVH, cardiac dysfunction and amyloid burden (175). T1 mapping techniques
provide new insights into this, being able to follow the disease at three different levels, i.e.
infiltration (amyloid burden, ECV), edema (native T1) and myocyte response (intracellular
volume) and providing new prognostic markers.(77) These new biomarkers may aid
diagnosis, risk stratifications and act as surrogate end points in clinical trials. However the
current limited availability, the technical challenges related to sequence and vendor
specific differences limit the role of T1 mapping in routine clinical practice. The common
use of the LGE technique in all clinical CMR scans and the availability of PSIR
reconstruction on all different vendor platforms make LGE a robust and reliable approach
for routine risk stratification of patients with cardiac amyloidosis.
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Limitations of the study are that patients are at different treatment stages, with treatment
reflecting current UK practice. Cardiac biopsy is present only in a minority of patients, but
this cohort of patients was fully characterized with all other clinical investigative techniques
currently available including DPD scanning. This composite diagnostic pathway is known
to provide high diagnostic accuracy. The causes of death are not known as patients die
locally and the National Amyloidosis centre only receives notification of death rather than
cause of death. Although this study highlights the prognostic role of transmural LGE for
risk stratification of patients with cardiac amyloidosis, further studies are needed to assess
the direct correlation between patterns of LGE and treatment related mortality.
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13. DISCUSSION AND CONCLUSION
13.1 BACKGROUND AND HYPOTHESES EXPLORED:
Cardiac amyloidosis remains challenging to diagnose and to treat. Key ‘red-flags’
that should raise suspicion include clinical features indicating multisystem disease and
concentric LV thickening on echocardiography in the absence of increased voltage on
ECG. The pattern of gadolinium enhancement on CMR appears to be very characteristic.
Confirmation of amyloid type is now possible in most cases through a combination of
immunohistochemistry, DNA analysis and proteomics.
But whilst developments in chemotherapy have improved the outlook in AL
amyloidosis, the prognosis of patients with cardiac involvement remains very poor. Senile
cardiac amyloidosis is probably greatly under-diagnosed. The inability to reconcile
advances in treatment strategies with improved outcomes reflects our incomplete
understanding of the biology of the disease process. This is likely because no technique
has been thus far able to feasibly image or quantify the amyloid burden and understand
the myocyte response. Being able to do so would undoubtedly improve our knowledge of
the differences between amyloid types and may allow therapy to be better targeted.
Recently, CMR with T1 mapping has been shown to measure the ECV and cardiac
amyloid burden. Furthermore ECV have been shown in AL to be an independent
prognostic marker and non-contrast CMR with native T1 to be a potentially useful tool for
the diagnosis of cardiac amyloid infiltration in AL patients.
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As a result of the work during my PhD:
1) I have refined the technique as described in chapter 8 to make T1 measurement and
ECV faster, more robust and therefore clinically more applicable.
2) I then explored, in chapter 9, the ability of native T1 measurement to detect cardiac
infiltration in patients with both AL and ATTR cardiac amyloidosis, providing a new clinical
test that can be used in patients with contraindication to gadolinium.
3) Using contrast to measure the ECV and combining this information with the myocardial
mass and native T1, I was able, as described in chapter 10, to non-invasively and directly
measure the amyloid burden and myocyte response, gaining unique insight in the
pathophysiology of cardiac amyloidosis.
4) In chapter 11 I have finally shown that LGE measured with PSIR is a robust, now widely
available technique that can be used for better patient stratification.
13.2 REFINING CLINICAL APPLICABILITY OF ECV MEASUREMENT
Before the work in this thesis, measurement of the ECV required with the FLASH IR
method, required 9 breath-holds before and after contrast administration, each lasting
around 14 seconds to acquire a single slice. This technique was very sentive to cardiac
arrhytmias and could not be used in patients with ectopics or atrial fibrillation.
In the first part of my PhD I compared the accuracy of the ECV measured using the
multibreath-hold T1 pulse sequence to the ECV measured with ShMOLLI, a new, faster
sequence of T1 mapping.
119
ShMOLLI allows a T1 map of a selected slice to be generated in a single breath-hold
over 9 heart beats. We found it to be faster and more reproducible than the the FLASH IR
method in amyloidosis. In chapter 8 I showed that that more patients were able to perform
ShMOLLI than the multibreath-hold technique, that ECV calculated by multibreath-hold T1
and ShMOLLI showed strong correlation, little bias and good agreement. ECV correlated
with histological collagen volume fraction by multibreath-hold ECV but better by ShMOLLI
ECV. Inter-study reproducibility demonstrated that ShMOLLI ECV trended towards greater
reproducibility than the multibreath-hold ECV.
In conclusion I showed that ECV quantification by single breath-hold ShMOLLI T1
mapping can measure ECV by EQ-CMR across the spectrum of interstitial expansion, it is
procedurally better tolerated, slightly more reproducible and better correlates with histology
compared to the older multibreath-hold FLASH techniques.
These advances have made the assessment of ECV a much simpler “add on” to a
clincal CMR scan, only requiring in addition, a haematocrit measurement.
13.3 NATIVE T1 IN ATTR AMYLOIDOSIS
Before my work, in ATTR cardiac amyloidosis only contrast CMR could detect non
invasivly cardiac involvement. However, administration of gadolinium chelates is
contraindicated in patients with severe kindey failure.
My work demonstrated the ability of native T1 measured with ShMOLLI to detect
cardiac infiltration in both types of cardiac amyloidosis. In chapter 9 I showed that T1 was
elevated in ATTR patients compared to patients with HCM and normal subjects. In
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established cardiac ATTR amyloidosis, T1 elevation was not as high as in AL amyloidosis.
Diagnostic performance was similar for AL and ATTR amyloid and T1 tracked cardiac
amyloid burden as determined semi-quantitatively by DPD scintigraphy. T1 was not
elevated in mutation carriers but was in isolated DPD grade 1.
These advances have provided a new diagnostic tool for the diagnosis of cardiac
infiltration in ATTR amyloidosis in patients with renal failure. A weakness persists that we
don’t have reference ranges (if needed) for subjects in end stage renal failure. The
possibility that their native T1 is elevated by ESRF is not yet explored.
13.4 DIFFERENTIAL MYOCYTE RESPONSE IN AL AND ATTR CARDIAC AMYLOIDOSIS
Prior to my work, the pathophysiological understanding of the mechanisms of
cardiac response to amyloid infiltration was very limited.
My work has provided unique insight in the pathophysiology of cardiac amyloidosis.
In chapter 10 I showed that that both the LV massi and ECV were markedly elevated in
amyloidosis, but the Total Cell Volume was normal in AL, but significantly elevated in
ATTR. The result is that all the increase in LV mass in AL is extracellular volume, whereas
the increase in ATTR is extracellular but within addition, an 18% increase in the intra-
cellular space.
These findings shows that cardiac amyloid deposits seem more extensive in ATTR
than in AL type, but that ATTR type is uniquely associated with myocyte hypertrophy.
Compensatory myocyte hypertrophy may contribute to the superior clinical outcome of
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ATTR amyloidosis. These results have provided unique understanding of the
pathophysiological mechanism behind the differences between ATTR and AL amyloidosis.
13.5 PROGNOSTIC VALUE OF LGE
Prior to my work, the potential of LGE for risk stratification of patients with cardiac
amyloidosis was unknown.
In chapter 11, I showed that LGE in patients with amyloidosis could be classified
into 3 different patterns: none, subendocardial and transmural, which were associated with
increasing amyloid burden as defined by ECV. Transmural LGE predicted death and
remained independent after adjusting for NT-proBNP, ejection fraction, stroke volume
index, E/E’ and left ventricular mass index.
These results showed that there is a continuum of cardiac involvement in systemic
AL and ATTR amyloidosis. Transmural LGE is determined reliably by PSIR and
represents advanced cardiac amyloidosis. The PSIR technique provides incremental
information on outcome even after adjusting for known prognostic factors.
These findings have provided a widely available prognostic marker for better risk
stratification of patients with AL and ATTR cardiac amyloidosis.
13.6 CLINICAL INSIGHTS AND POTENTIAL
Cardiac infiltration is the chief driver of prognosis in systemic amyloidosis. Its assessment
aids patient selection to receive (or not) aggressive chemotherapy, stem cell therapy and
newer therapies. Currently, stratification uses blood biomarkers and echocardiography -
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but echocardiography has limited sensitivity and specificity particularly in apparently early
disease and where confounders are present (such as hypertension). Cardiovascular
Magnetic Resonance shows promise with T1 mapping and Late Gadolinium Enhancement
(LGE) technique to visualise infiltration.
T1 mapping, now with new, faster and more robust sequences, is a useful diagnostic tool
to quantify amyloid infiltration and diagnose cardiac amyloidosis also in patients with
kidney failure. With the administration of the contrast, throughout the measurement of ECV
and myocyte volume, provide unique insights in the pathophysiology of cardiac
amyloidosis: the disease is not only about amyloid infiltration, the myocyte response is
essential to understand the differences in natural history and prognosis between the types.
Finally LGE with PSIR is a robust widely available technique that can be used both for
diagnosis and better risk stratification of patients with cardiac amyloidosis. This could
potentially save patient lives not only from the disease itself, but possibly even reduce
some of the treatment-related mortality.
However, it is important to balance this with recognition of the current limitations. I
have not been able to histologically validate the technique so the technique cannot yet be
deemed to be a true non-invasive quantifier of cardiac amyloid burden.
Furthermore, although LGE has emerged as independently predictive of survival in
multivariate analysis, it is unclear how much this will impact on and change current clinical
management which relies heavily on Troponin T and NT-pro BNP; if one considers LGE as
a biomarker, it is more expensive than Troponin T and NT-pro BNP although if one
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considers the additional information gained from cardiac MRI as a whole, this may
represent a more cost-effective strategy overall – further studies are needed.
There are also standardisation challenges yet to be addressed across different
centres with MRI.
FUTURE WORK:
This thesis has looked at the diverse uses of CMR T1 mapping based methodology
to assess systemic amyloidosis.
Work is needed to establish histological validation of ECV with cardiac histology.
This is challenging not only because of the obvious invasive nature of biopsy, but also
because of the need to correlate the timing of biopsy within an acceptable time-frame of
the EQ-CMR scan, something which is not easy when patients live so far away. The ideal
staining method to differentiate amyloid from fibrosis in a manner which is still quantifiable
by computer software remains an ongoing challenge too.
ECV measurements in extracardiac organs also requires standardising. The ideal
method of T1 mapping the liver and spleen remains undetermined and where to draw
ROIs in the liver requires universal agreeement. Further work is also needed in evaluating
the role of ECV and T1 in ATTR amyloidosis – this is already work in progress.
From an MRI perspective, the T1 mapping sequences are constantly improving e.g.
the ShMOLLI sequence currently does not correct for any motion artefacts which makes it
more likely to result in partial voluming with blood at the edges of a myocardial ROI – such
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sequences are work in progress.204 There has also been very little work comparing the
reproducibility T1 and ECV across multiple sites and using MRI equipment from differing
vendors.
From a more general perspective, myocardial T1 and ECV assessment is a new
field and there is little agreement between groups as to what terminology should be used
e.g. extracellular volume (ECV), extracellular volume fraction (ECVF), myocardial volume
of distribution (Vd(m)) have all been used by different groups to describe the same thing
over the last 2-3 years. An initiative from this hospital (Prof. James Moon) has therefore
set up a T1 mapping development group which has now met 7 times and published a
consensus statement for everyone in the field to use as a baseline guide.
My work has triggered a number of key changes and progressions, specifically:
1. The NAC now routinely transfers patients to the Heart Hospital for CMR scanning and
T1 mapping to calculate ECV which was not previously the case.
2. ECV results now play a key role in the weekly MDT meetings when determining the
timing and choice of treatment.
3. My work comparing ECV to SAP scanning in AL amyloidosis has laid the groundwork
for similar research in comparing ECV with DPD scanning in ATTR amyloidosis. This
work has already begun and the preliminary findings were shortlisted at the Young
Investigator Awards at the 2014 AHA scientific sessions in Chicago, USA.
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4. My work with ECV in the liver and spleen in AL amyloidosis has attracted the attention
of the pharmaceutical industry who are now using ECV of the liver and spleen as an
endpoint for their first in man study of therapy in systemic AL amyloidosis, following my
presentation of this data at the International Amyloidosis Symposium in 2012. The first
paper by GSK is published in NEJM
5. National commissioning is centrally funding 500 amyloid scans a year for the NAC
6. The National Amyloid Centre is installing a dedicated CMR department with 50% time
for amyloid. The magnet is delivered second week in October. The advert for lead of
the department is out and I am short-listed for interview in October.
13.7 CONCLUSION:
This thesis has provided further insight into the field of cardiac amyloidosis. CMR with T1
mapping and LGE has unique ability to show and quantify amyloid infiltration. My thesis
shows the huge potential of these techniques and lays a path for future work in the field to
ultimately benefit and improve patient outcomes from this rare but fatal disease.
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